

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A Novel Point-Of-Care Cytokine Biomarker Lateral Flow Test for the Screening for Sexually Transmitted Infections and Bacterial Vaginosis: Study Protocol of a Multi-Centre Multi-Disciplinary Prospective Clinical Study to Evaluate the Performance and Feasibility of the Genital Inflammation Test (GIFT).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-084918
Article Type:	Protocol
Date Submitted by the Author:	02-Feb-2024
Complete List of Authors:	<p>RAMBOARINA, Stephanie; Institut Pasteur de Madagascar, Unit of Experimental Bacteriology  Crucitti, Tania; Institut Pasteur de Madagascar, Experimental Bacteriology Unit  Gill, Katherine ; University of Cape Town, IDDM; Desmond Tutu HIV Foundation  Bekker, Linda Gail; Desmond Tutu HIV Foundation; University of Cape Town, IDDM  Harding-Esch, Emma; London School of Hygiene and Tropical Medicine van de Wijgert, Janneke H.H.M.; University Medical Centre Utrecht, Julius Center for Health Sciences and Primary Care  Huynh, Bich-Tram; Pasteur Institute,  Fortas, Camille; Pasteur Institute  Harimanana, Aina; Institut Pasteur de Madagascar  Mayouya Gamana, Théodora; Institut Pasteur de Madagascar  Randremarana, Rindra Vatosoa; Institut Pasteur de Madagascar, Epidemiology Unit  Mangahasimbola, Reziky; Institut Pasteur de Madagascar  Dziva Chikwari, Chido; London School of Hygiene &amp; Tropical Medicine; Organization for Public Health Interventions and Development  Kranzer, Katharina; London School of Hygiene and Tropical Medicine, Clinical Research Department; Medical Center of the University of Munich, Division of Infectious Diseases and Tropical Medicine  Mackworth-Young , Constance ; London School of Hygiene and Tropical Medicine  Bernays , Sarah; The University of Sydney, School of Public Health; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, Global Health and Development  Thomas, Nicola; Desmond Tutu HIV Foundation; University of Cape Town  Anderson, David; Burnet Institute,  Tanko, Fatime; University of Cape Town, Division of Medical Virology; MRC, Institute of Medical Research and Medicinal Plant Studies  Manhanzva, Monalisa; University of Cape Town, IDDM; Centre for the Aids Programme of Research in South Africa  Khumalo, Fezile; University of Cape Town, IDDM; Centre for the Aids</p>

	Programme of Research in South Africa Sinanovic, Edina; University of Cape Town, Health Economic Unit, School of Public Health, Faculty of Health Sciences Honda, Ayako; Hitotsubashi University, Research Center for Health Policy and Economics Pidwell, Tanya; University of Cape Town, IDDM Francis, Suzanna ; London School of Hygiene and Tropical Medicine Masson, Lindi; Burnet Institute; University of Cape Town, IDDM Passmore, Jo-Anne; University of Cape Town, IDDM; Centre for the Aids Programme of Research in South Africa 'The Gift Study group, '; Institut Pasteur de Madagascar, Unit of Experimental Bacteriology; University of Cape Town, IDDM
Keywords:	Sexually Transmitted Disease, BACTERIOLOGY, Public health < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2 **A Novel Point-Of-Care Cytokine Biomarker Lateral Flow Test for the Screening for Sexually**  
3 **Transmitted Infections and Bacterial Vaginosis: Study Protocol of a Multi-Centre Multi-**  
4 **Disciplinary Prospective Clinical Study to Evaluate the Performance and Feasibility of the**  
5 **Genital Inflammation Test (GIFT).**  
6  
7  
8  
9

10 Stéphanie Ramboarina<sup>1\*</sup>, Tania Crucitti<sup>1\*</sup>, Katherine Gill<sup>2</sup>, Linda-Gail Bekker<sup>2</sup>, Emma M Harding-  
11 Esch<sup>3</sup>, Janneke H H M van de Wijgert<sup>4</sup>, Bich-Tram Huynh<sup>5,6</sup>, Camille Fortas<sup>5,6</sup>, Aina Harimanana<sup>1</sup>,  
12 Théodora Mayouya Gamana<sup>1</sup>, Rindra Randremanana<sup>1</sup>, Reziky Mangahasimbola<sup>1</sup>, Chido Dziva  
13 Chikwari<sup>3,7,8</sup>, Katarina Kranzer<sup>3,9</sup>, Constance R S Mackworth-Young<sup>3</sup>, Sarah Bernays<sup>3,10</sup>, Nicola  
14 Thomas<sup>2</sup>, David Anderson<sup>11</sup>, Fatime-Ramla Tanko<sup>12,13,14,17</sup>, Monalisa Manhanzva<sup>12,14,17</sup>, Micaela  
15 Lurie<sup>12,14,17</sup>, Fezile Kumalo<sup>12,14,17</sup>, Edina Sinanovic<sup>15</sup>, Ayako Honda<sup>16</sup>, Tanya Pidwell<sup>12</sup>, Suzanna  
16 Francis<sup>3</sup>, Lindi Masson<sup>\$11,12,14,18,19</sup>, Jo-Ann Passmore<sup>\$12,14,17,19</sup> and the GIFT study group.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 \*Equal contribution

31 \$ Equal contribution

32  
33  
34  
35  
36 <sup>1</sup> Institut Pasteur de Madagascar, Madagascar

37  
38 <sup>2</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa

39  
40 <sup>3</sup> London School of Hygiene & Tropical Medicine, England

41  
42 <sup>4</sup> Julius Center University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands

43  
44 <sup>5</sup> Institut Pasteur, Université Paris Cité, France

45  
46 <sup>6</sup> Université Paris-Saclay, Université Versailles Saint-Quentin, Inserm, France

47  
48 <sup>7</sup> Organization for Public Health Interventions and Development, Zimbabwe

49  
50 <sup>8</sup> The Biomedical Research and Training Institute, Zimbabwe

51  
52 <sup>9</sup> Division of Infectious Diseases and Tropical

53  
54  
55  
56  
57  
58  
59  
60  
Medicine, Medical Center of the University of Munich, Munich, Germany

<sup>10</sup> School of Public Health, University of Sydney, Australia

1  
2 <sup>11</sup> Disease Elimination Program, Life Sciences Discipline, Burnet Institute, Australia

3  
4 <sup>12</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa

5  
6 <sup>13</sup> The Medical Research Centre, Institute of Medical Research and Medicinal Plant Studies  
7  
8 (IMPM), Ministry of Scientific Research and Innovation, Yaoundé, Cameroon

9  
10  
11 <sup>14</sup> Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South  
12  
13 Africa

14  
15 <sup>15</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
16  
17 Town, South Africa

18  
19 <sup>16</sup> Research Center for Health Policy and Economics, Hitotsubashi Institute for Advanced Study,  
20  
21 Hitotsubashi University, Japan

22  
23 <sup>17</sup> Centre for the AIDS Programme of Research in South Africa, South Africa

24  
25 <sup>18</sup> Central Clinical School, Monash University, Australia

26  
27 <sup>19</sup> National Health Laboratory Service, Cape Town, South Africa

28  
29  
30  
31  
32  
33  
34 **GIFT study group**

35  
36 Eneyi Kpokiri<sup>1</sup>, Bahiah Meyer<sup>2</sup>, Phumla Radebe<sup>2</sup>, Conita Lombard<sup>2</sup>, Celia Mehrou-Loko<sup>2</sup>,  
37  
38 Yacoeb Ganief<sup>2</sup>, Rezeen Daniels<sup>3</sup>, Anda Madikida<sup>3</sup>, Karabo Mahlangu<sup>3</sup>, Tinashe Mwaturura<sup>4,5</sup>,  
39  
40 Mutsawashe Chisenga<sup>4,5</sup>, Joseph F Chipanga<sup>4,5</sup>, Tsitsi Bandason<sup>4,5</sup>, Patricia Makunyire<sup>4,5</sup>, Felicia  
41  
42 Mhangami<sup>4,5</sup>, Jayjay Karumazondo<sup>5</sup>, Jason Naidoo<sup>5</sup>, Karen Webb<sup>4</sup>, Lyndon Mungur<sup>6</sup>, Ashley Uys<sup>6</sup>,  
43  
44 Darryl Uys<sup>6</sup>, Elise Smith<sup>7</sup>, Saberi Marias<sup>8</sup>, Solange Rasoanandrianina<sup>9</sup>, Dimitri Ravoavison<sup>9</sup>,  
45  
46 Patrick Andry Rakotonirina<sup>9</sup>, Andrilaina Razakarivony<sup>9</sup>, Hantamalala Randria<sup>9</sup>, Alphonsine  
47  
48 Rahantarimalala<sup>9</sup>, Lala Rafetrarivony<sup>10</sup>, Barivola Bernardson<sup>10</sup>, Tsiry Rasolofomanana<sup>10</sup>,  
49  
50 Norohasina Randriamange<sup>10</sup>, Antsanirina Nomenjanahary<sup>10</sup>, Laurah Rabarisoa<sup>10</sup>, Dimitri  
51  
52 Rasoloson<sup>10</sup>, Sahara Raveloson<sup>10</sup>, Laura Randrianantenaina<sup>10</sup>, Hanitratiavina Rakotonindriana<sup>10</sup>,  
53  
54 Fenosoa Voanarivolalao<sup>10</sup>, Vaomalala Ranarinandra<sup>10</sup>, Farai Machinga<sup>11</sup>

1  
2 <sup>1</sup> London School of Hygiene & Tropical Medicine, United Kingdom  
3

4 <sup>2</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa  
5

6 <sup>3</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa  
7

8 <sup>4</sup> Organization for Public Health Interventions and Development, Zimbabwe  
9

10 <sup>5</sup> The Biomedical Research and Training Institute, Zimbabwe  
11

12 <sup>6</sup> Medical Diagnostech, Cape Town, South Africa  
13

14 <sup>7</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
15  
16  
17  
18 Town, South Africa

19 <sup>8</sup> Research Contracts and Innovation, University of Cape Town, South Africa  
20

21 <sup>9</sup> Centre Hospitalier Universitaire de Gynécologie et Obstétrique de Befelatanana, Antananarivo,  
22  
23  
24  
25 Madagascar

26 <sup>10</sup> Institut Pasteur de Madagascar, Madagascar  
27

28 <sup>11</sup> National Family Planning Council, Zimbabwe  
29

30  
31  
32  
33  
34 **Corresponding author:** Tania Crucitti, Experimental Bacteriology Unit, Institut Pasteur de  
35  
36 Madagascar, B.P. 1274. Ambatofotsikely - 101 Antananarivo, Madagascar. Tel : +261 20 22 412  
37  
38  
39 72. [tcrucitti@pasteur.mg](mailto:tcrucitti@pasteur.mg)  
40

41  
42  
43 **Word count: 6200**  
44

45 **Keywords:** Sexually transmitted infections, bacterial vaginosis, lateral flow point of care test,  
46  
47  
48 cytokines, genital inflammation test.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

A prototype lateral flow device detecting cytokine biomarkers IL-1 $\alpha$  and IL-1 $\beta$  has been developed as a Point-of-Care (POC) test – called the Genital InFLammation Test (GIFT) - for detecting genital inflammation associated with sexually transmitted infections (STIs) and/or bacterial vaginosis (BV) in women. In this paper, we describe the rationale and design for studies that will be conducted in South Africa, Zimbabwe, and Madagascar to evaluate the performance of GIFT and how it could be integrated into routine care.

### Methods and analysis

We will conduct a prospective, multidisciplinary, multi-centre, and cross-sectional clinical study comprising two distinct components: a biomedical (“diagnostic study”) and a qualitative, modelling, and economic (“an integration into care study”) part. The diagnostic study aims to evaluate GIFT’s performance in identifying asymptomatic women with discharge-causing STIs (*Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Trichomonas vaginalis* (TV) and *Mycoplasma genitalium* (MG)) and BV. Study participants will be recruited from women attending research sites and family planning services. Several vaginal swabs will be collected for evaluation of cytokine concentrations (enzyme-linked immunosorbent assay), STIs (nucleic acid amplification tests), BV (Nugent Score), and vaginal microbiome characteristics (16S rRNA gene sequencing). The first collected vaginal swab will be used for the GIFT assay which will be performed in parallel by a healthcare worker in the clinic near the participant, and by a technician in the laboratory. The integration into care study aims to explore how GIFT could be integrated into routine care. Four activities will be conducted: user experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews with key stakeholders; discrete choice experiments; development of a decision tree classification algorithm; and economic evaluation of defined management algorithms.

## Ethics and dissemination

The study was approved by the ethical committees in Madagascar, South Africa and Zimbabwe.

## Strengths and limitations of this study

- A multicountry evaluation of a new low-cost rapid POC test detecting vaginal inflammation to be conducted in three sub-Saharan countries characterized by different STI/BV contexts.
- Multidisciplinary approach including social science, economic analysis and machine learning to inform how the GIFT device could be integrated into STI management algorithms for women.
- Sensitization on genital inflammation including STI/BV among young non-pregnant women.
- The budget does not permit STI diagnosis using POC NAAT testing in Madagascar, in contrast to South Africa and Zimbabwe, leading to presumptive treatment aligning with the usual routine care practices.
- The user evaluation of the GIFT device does not include the evaluation nor quality assessment of the specimen extraction method.



## Introduction

Sexually transmitted infections (STIs) continue to pose a significant health challenge globally, with over one million new cases reported daily. In 2020, approximately 377 million new cases of the four most common STIs (*Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), syphilis, and *Trichomonas vaginalis* (TV)) were documented, with over 70% occurring in low- and middle-income countries (LMICs), particularly in Sub-Saharan Africa and Latin America [1].

STIs impact women more than men, as women endure long-lasting consequences. Additionally, women are more susceptible to STIs than men due to anatomical and immunological differences [2,3]. The composition of the vaginal microbiome also plays a crucial role in sexual and reproductive health. Optimal vaginal microbiota, predominantly composed of *Lactobacillus* species, maintains an acidic pH, sustaining the vaginal epithelial barrier's integrity and preventing pathogen colonisation and invasion. However, various genetic, behavioural, and environmental factors can modulate this microbial composition and lead to bacterial vaginosis (BV) characterised by a decrease in protective *Lactobacillus* species along with an increase in bacterial diversity and vaginal pH [4-9].

BV remains a persistent public health issue, with prevalences ranging from 20-30% globally, and higher rates observed in Black populations compared to Caucasian or Asian populations [4, 6, 10]. In Sub-Saharan African populations, prevalences are notably high (around 33%) [10].

Both STIs and BV induce elevated genital inflammation, marked by increased local production of pro-inflammatory cytokines and chemokines, irrespective of symptoms [7, 11, 12, 13-15]. Studies in Sub-Saharan African women cohorts have shown that common STIs such as CT, NG, and TV significantly and consistently increased the concentrations of key genital tract cytokine biomarkers, including interleukin (IL)-1 $\alpha$  and  $\beta$  [14, 16, 17]. BV caused similar changes in these cytokine biomarkers, although was also shown to be associated with lower concentrations of the chemokine

1  
2 interferon- $\gamma$ -induced protein of 10kDa (IP-10) [12, 18, 19]. Genital inflammation caused by STIs  
3  
4 and BV has in turn been associated with increased risk for the acquisition of other STIs, including  
5  
6 HIV-1 [20-25]. This is particularly concerning in Sub-Saharan African countries, where a  
7  
8 significant proportion of new HIV-1 infections occur. The HIV-1 prevalence among adults (15-49  
9  
10 years) was estimated at 17.8% and 11% in South Africa and Zimbabwe, respectively in 2022.  
11  
12 Women are disproportionately affected by HIV than men, with young women (15-24 years)  
13  
14 particularly vulnerable with prevalence rates estimated at 8.7% and 4.4% in South Africa and  
15  
16 Zimbabwe, respectively [26].  
17  
18  
19

20  
21 Both STIs and BV are also associated with other serious sexual and reproductive health  
22  
23 complications, such as pelvic inflammatory disease which can lead to infertility and ectopic  
24  
25 pregnancy and adversely affect woman's reproductive plans. For prevalent bacterial STIs and BV,  
26  
27 intrauterine infection and/or vertical transmission to the unborn child or during birth can result in  
28  
29 adverse pregnancy and birth outcomes, including preterm delivery, maternal and neonatal sepsis,  
30  
31 low birth weight, pneumonia, and conjunctivitis in the newborn [3, 27].  
32  
33  
34  
35

36  
37 Despite the high prevalence of STIs and BV, and their frequently asymptomatic nature, syndromic  
38  
39 approaches remain the mainstay of management in LMICs [28]. Immediate testing and results  
40  
41 delivery are crucial to facilitate prompt diagnosis and accurate treatment, reducing both STI  
42  
43 transmission and infection progression [29-31]. Consequently, the inclusion of POC tests has been  
44  
45 highly recommended for the management of symptomatic STIs [28]. Recently, nucleic acid  
46  
47 amplification-based near-patient STI diagnostics have become available [32, 33], but none of them  
48  
49 fulfills the REASSURED (including user-friendly, rapid, robust, equipment-free, and deliverable to  
50  
51 end-users) criteria set out by World Health Organization (WHO) for POC tests [34].  
52  
53  
54

55  
56 Genital inflammation has been associated with a significantly increased risk of HIV acquisition in  
57  
58 women and the presence of STIs driving this inflammation has been well described among South  
59  
60 African women [11, 16, 22, 25]. To address the need for POC tests to improve STI/BV

1  
2 management for women in LMICs, Masson *et al.* have focused on developing a POC lateral flow  
3  
4 test to detect a combination of inflammation biomarkers (IL-1 $\alpha$ , IL-1 $\beta$ , and IP-10), measured in  
5  
6 lateral vaginal wall swabs, to improve BV and STI case finding in women compared to clinical  
7  
8 signs [20]. This Genital Inflammation Test (GIFT) screening tool aims to improve case detection to  
9  
10 help identify women at increased risk of HIV infection and to enhance the sexual and reproductive  
11  
12 health of women in countries where only syndromic management is available.  
13  
14  
15

16  
17 This study protocol outlines a study to be conducted in three countries (South Africa, Zimbabwe,  
18  
19 and Madagascar) to evaluate the performance of the first-in-field GIFT prototype device and  
20  
21 explore possible routes for integration into routine care.  
22  
23

### 24 **Purpose and study objectives**

25  
26  
27 This multidisciplinary, cross-sectional, prospective, and multi-centric study has two distinctive sub-  
28  
29 studies, a diagnostic evaluation and an integration into care study. Each sub-study has several  
30  
31 objectives (Table 1).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1:** GIFT study objectives

	Diagnostic study	Integration into care study
<b>Primary objective</b>	To assess the sensitivity and specificity of the GIFT device at the point-of-care in South Africa, Zimbabwe, and Madagascar.	To evaluate how the GIFT device could be integrated into routine care
<b>Secondary objectives</b>	<ul style="list-style-type: none"> <li>To assess the predictive values of the GIFT device at the point-of-care</li> <li>To assess the performance of the GIFT device at the point-of-care</li> <li>To assess the performance of the device versus syndromic management without any laboratory testing (standard of care in South Africa, Zimbabwe, and Madagascar)</li> <li>To determine the robustness of the device by comparing results read by clinicians with those read by laboratory professionals, and with the results obtained using an automated reader</li> <li>To evaluate the accuracy of the GIFT device by comparing the GIFT device results with ELISA results using previously validated concentration cut-offs as the gold standard, including validation of the GIFT cytokine concentration cut-offs for each cytokine biomarker.</li> </ul>	<ul style="list-style-type: none"> <li>To qualitatively and quantitatively assess the user experience, usability, and acceptability of the GIFT device at the point of care;</li> <li>To examine patient preferences for various STI management aspects (attributes) to inform the development of STI management algorithms that integrate the GIFT device;</li> <li>To generate algorithms that integrate the GIFT device to optimise case finding and STIs/vaginal infection management in women, using the complete dataset from the study;</li> <li>To determine the cost and budget impact of the identified screening or diagnostic algorithm with the GIFT device, and to model the cost-effectiveness of different strategies of integration of GIFT into care.</li> </ul>
<b>Exploratory objectives</b>	<ul style="list-style-type: none"> <li>Determine if other determinants (such as intermediate microbiota (Nugent 4-6), age, parity, sexual activity) improve the prediction of STI/BV status in women</li> <li>To use 16S rRNA gene sequencing and vaginal bacteria specific quantitative NAATs to evaluate the proportion of cases of genital inflammation explained by vaginal dysbiosis that was not diagnosed as an STI or BV by NAATs or Nugent scoring</li> <li>To explore the performance of the device in the presence of vaginal <i>Candida spp</i> colonisation.</li> </ul>	

1  
2 The diagnostic study aims to evaluate the performance of GIFT in identifying women with  
3  
4 inflammatory STIs (including CT, NG, TV and MG) and BV and who may, therefore, be at higher  
5  
6 risk of STI and HIV infection and potential reproductive complications. Syndromic management in  
7  
8 the absence of any diagnostic testing misses all asymptomatic reproductive tract infections by  
9  
10 definition, and GIFT may detect the presence of asymptomatic subclinical inflammation.  
11  
12 Syndromic management guidelines currently call for women with cervicovaginal discharge to be  
13  
14 treated for all reproductive tract infections that might cause such discharge, but studies have shown  
15  
16 that a substantial proportion of these women do not have any infection [29]. In this scenario, GIFT  
17  
18 may prevent overtreatment of symptomatic women without infection.  
19  
20  
21  
22

23  
24 The primary objective is to assess the sensitivity and specificity of the GIFT device at the point-of-  
25  
26 care in non-pregnant sexually active women aged 18-35 years accessing family planning services in  
27  
28 South Africa, Zimbabwe, and Madagascar against nucleic acid amplification tests (NAATs) for CT,  
29  
30 NG, TV, and MG plus BV by Nugent scoring (Table 1). Secondary objectives include assessing the  
31  
32 device's predictive values; assessing performance in each country separately; assessing  
33  
34 performance against syndromic management; assessing test reproducibility by comparing clinician-  
35  
36 and laboratory-read results (visual reading versus automated reader); and setting the device's  
37  
38 concentration cut-offs against gold standard cytokine concentrations (determined by enzyme-linked  
39  
40 immunosorbent assay (ELISA)).  
41  
42  
43  
44

45  
46 The integrative part of the study aims to explore the feasibility, acceptability, and cost-effectiveness  
47  
48 of integrating GIFT into routine care in LMICs. The specific objectives include: assessing the user-  
49  
50 experience, usability, and acceptability of the GIFT device at the POC; examining patient  
51  
52 preferences for various STI management aspects to develop STI management algorithms;  
53  
54 generation of algorithms that integrate the GIFT device to optimise case finding and STI/vaginal  
55  
56 infection management in women; and determine the cost-effectiveness and budget impact of the  
57  
58 identified algorithms with the GIFT device.  
59  
60

## Methods and design

### *Study design*

The diagnostic study will target women attending family planning services in each of the three study sites in South Africa, Zimbabwe, and Madagascar. A series of vaginal swabs will be collected by a midwife or nurse (Figure 1).

The first swab will be used to test the performance of the GIFT device. For each woman, the GIFT will be performed twice and read four times: one GIFT will be performed at the clinical site near the participant and visually read by a midwife or study nurse and a second GIFT will be done and visually read by a technician in the laboratory. The GIFT assays carried out by the midwife/study nurse and the laboratory technician will secondly be read using an automated lateral flow reader (Axxin, Fairfield, Australia) (Figure 1). The GIFT device performance in detecting (1) inflammation will be determined against cytokine enzyme-linked immunosorbent assay (ELISA); and (2) STIs/BV will be determined against the NAAT reference tests for CT, NG, TV and MG and Nugent scoring for BV (Figure 1). All women will be offered treatment based on the on-site positive STI diagnostic results for CT, NG, and TV. Additionally, treatment for BV will be offered based on the Nugent score analysis and at the clinician's discretion.

The integration into care study consists of four activities to determine how GIFT can be integrated in a feasible, acceptable, and cost-effective way into routine care and national guidelines in South Africa, Zimbabwe and Madagascar (Figure 2): 1. User experiences and/or perceptions of the GIFT device involving qualitative focus group discussions (FGDs) and in-depth interviews (IDIs) with key stakeholders; 2. Discrete choice experiment (DCE); 3. Development of a decision tree classification algorithm; 4. Economic evaluation of defined management algorithms.

### *Study sites*

1  
2 The study will be performed in three countries: South Africa, Zimbabwe, and Madagascar. In  
3  
4 contrast to South Africa and Zimbabwe which are countries bearing a high burden of STIs,  
5  
6 including HIV, and BV [35-37], data on STI/BV prevalence are relatively scarce in Madagascar.  
7  
8 BV, TV, and cervical infections (CT and NG) prevalences measured in a large population sample of  
9  
10 symptomatic Malagasy women (N=1066) were high at 53%, 24%, and 17% respectively,  
11  
12 suggesting a significant burden of STIs/BV in the island [38]. Finally, Madagascar is less affected  
13  
14 by HIV with a prevalence <1% [39] compared to South Africa and Zimbabwe, which were found to  
15  
16 have an HIV-1 prevalence among adults (15-49 years) in 2022 of 17.8% and 11%, respectively  
17  
18 [26].  
19  
20  
21

22 In South Africa, the study will be conducted at the Desmond Tutu Health Foundation (DTHF)  
23  
24 Masiphumelele Youth Centre located in the South peninsula of Cape Town. The Masiphumelele  
25  
26 Research Site has been recognised as a pioneer in HIV prevention and adolescent research. The STI  
27  
28 and BV diagnostic testing of the South African participants will be performed in their on-site  
29  
30 laboratory. In addition, vaginal swabs collected at all three study sites will be tested for selected  
31  
32 cytokines including IL-1 $\alpha$ , IL-1 $\beta$ , and IP-10 by ELISAs and for vaginal microbiome composition  
33  
34 by 16S rRNA gene sequencing being conducted at the University of Cape Town (UCT), along with  
35  
36 samples from the other two trial sites.  
37  
38  
39  
40

41 In Zimbabwe, the study will be conducted at the Spilhaus Family Planning Centre located in the  
42  
43 capital Harare. The study site is run by the Zimbabwe National Family Planning Council (ZNFPC)  
44  
45 in collaboration with the Zimbabwe Ministry of Health and Child Care. The study will be  
46  
47 conducted by researchers from the Organization for Public Health Interventions and Development  
48  
49 (OPHID), equipped with a skilled medical and technical team. The study site's laboratory will  
50  
51 perform the STI and BV diagnostic testing for Zimbabwean study participants.  
52  
53  
54  
55

56 In Madagascar, the study will be conducted at the Centre Hospitalier Universitaire de Gynécologie  
57  
58 et d'Obstétrique Gynéco-Obstétricaux de Befelatanana (CHU-GOB), a public university hospital  
59  
60 that specialises in obstetrics located in the capital of Madagascar, Antananarivo. Outpatient services

1  
2 include prenatal consultations, family planning, obstetrics, and gynaecology services. Due to the  
3  
4 lack of recent data on STI/BV prevalences, a pre-study on CT, NG, TV and MG prevalences was  
5  
6 conducted by the clinical and research team of IPM from March to December 2022 to confirm the  
7  
8 feasibility of conducting the GIFT study in the CHU-GOB in Antananarivo. The pre-study  
9  
10 confirmed the appropriateness of the clinical study site in terms of the study population's number  
11  
12 and STI and BV prevalence rates (results will be presented elsewhere).  
13  
14  
15

16 The unit of experimental bacteriology (UBEX) at the Institut Pasteur Madagascar (IPM) will be the  
17  
18 study site's laboratory in Madagascar for diagnostic testing. UBEX is also designated as the  
19  
20 reference laboratory in the GIFT project for BV and STI (CT, NG, TV and MG) comparator testing,  
21  
22 as well as quantification of lactobacilli and BV-associated bacteria using quantitative PCR and  
23  
24 molecular testing for the detection of *Candida* spp., and Y chromosome.  
25  
26  
27

### 28 *Study participants and recruitment*

29  
30 The diagnostic study will enroll its participants from sexually active women aged 18-35 years  
31  
32 attending family planning services in each of the study's clinical sites, irrespective of symptoms.  
33  
34 Prior to study initiation, advice will be sought from local Community Advisory Boards (CABs) or  
35  
36 similar committees on the study material to be shared with potential study participants. The boards  
37  
38 will be regularly consulted regarding language to use for behavioural and other sensitive questions  
39  
40 included in the questionnaires. A CAB is currently not existing in Madagascar but will be installed  
41  
42 as part of the study.  
43  
44  
45

46 Due to the short recruitment period, sensitisation to the GIFT project will be extended in  
47  
48 Antananarivo (Madagascar) to the family planning services of surrounding primary health care  
49  
50 centres. In South Africa, the clinical study site offers family planning services to young women till  
51  
52 the age of 25, and women outside of the study site will be recruited to enroll women between 25  
53  
54 and 35 years old.  
55  
56  
57

58 Women interested in the diagnostic study will be invited to participate based on the inclusion and  
59  
60 exclusion criteria detailed in Table 2. Each woman will only be enrolled once.



**Table 2:** In- and exclusion criteria for both diagnostic and integration into care studies

	Diagnostic study	Integration into care study
<b>Inclusion criteria</b>	<ul style="list-style-type: none"> <li>• 18-35 years old</li> <li>• Willing and able to provide informed consent to participate in the study</li> <li>• Self-reported to be sexually active</li> <li>• Not pregnant (determined by pregnancy test)</li> <li>• Accessing family planning service</li> </ul>	<p>For all who are willing and able to provide informed consent to participate in the study.</p> <ul style="list-style-type: none"> <li>• User experiences/perceptions activity: <ul style="list-style-type: none"> <li>- Local or regional policymakers, programmers, and other opinion leaders and decision-makers</li> <li>- Healthcare professionals at health facilities</li> <li>- Women who are eligible for the diagnostic study (including pregnant and menstruating women), but who are not part of the diagnostic study</li> </ul> </li> <li>• Discrete choice experiments: Women who are eligible for the diagnostic study (including pregnant and menstruating women), who are either part of, or not part of, the diagnostic study</li> <li>• Decision tree classification algorithm: Data from diagnostic study participants</li> <li>• Economic evaluation: Healthcare professionals at health facilities involved in GIFT device implementation able to complete timesheets</li> </ul>
<b>Exclusion criteria</b>	<ul style="list-style-type: none"> <li>• &lt;18 years or &gt;35 years</li> <li>• Refusal by a participant to participate in the study</li> <li>• Treatment for any STI/BV in the past 30 days</li> <li>• Pregnancy</li> <li>• Enrolled in a study that does not allow co-enrolment in other studies</li> </ul>	<p>For all who are not willing or able to provide informed consent to participate in the study</p> <ul style="list-style-type: none"> <li>• User experiences/perceptions activity: <ul style="list-style-type: none"> <li>- Non-relevant policymakers</li> <li>- Healthcare professionals at health facilities not included in diagnostic study</li> </ul> </li> <li>- Women who are : <ul style="list-style-type: none"> <li>▸ part of the diagnostic study</li> <li>▸ &lt;18 years or &gt;35 years</li> <li>▸ Treated for any STI/BV in the past 30 days</li> <li>▸ Pregnant</li> <li>▸ Enrolled in a study that does not allow co-enrolment in other studies</li> </ul> </li> <li>• Decision tree classification algorithm: Participants for whom there are no diagnostic study data</li> <li>• Economic evaluation: Healthcare professionals not at study sites, not involved in GIFT device implementation, and/or not able to complete timesheets</li> </ul>

1  
2 In addition to eligible women participating in the diagnostic study, participants for the integration  
3 into care study will include health care professionals (HCPs) including nurses, midwives, and  
4 matrons working at the clinical site where the diagnostic study is being conducted, women  
5 attending gynaecological consultations at the study clinic, local and regional policymakers,  
6 programmers, other opinion leaders, and decision-makers according to the inclusion and exclusion  
7 criteria (Table 2).  
8  
9  
10  
11  
12  
13  
14

### 15 16 *Sample size*

17  
18 A total number of 675 women (225 women per site) will be enrolled for the diagnostic evaluation of  
19 the prototype GIFT device. The sample size calculation is based on 7% precision, and an assumed  
20 sensitivity of 77% and a specificity of 71% of GIFT compared to NAATs for STIs and Nugent  
21 scoring for BV [40].  
22  
23  
24  
25  
26  
27

28  
29 No sample size calculations were performed for the qualitative research. A purposive sampling  
30 strategy will be adopted to reflect maximum variation, as feasible, across the sample. It is  
31 anticipated that the proposed number of participants per activity (FGDs and IDIs), per country, will  
32 enable adequate data to be collected and saturation to be reached in the thematic analysis [41, 42].  
33  
34  
35  
36  
37  
38 Data collection may be finalised before the planned sample size is reached, if saturation is reached  
39 first.  
40  
41

42  
43 For the DCE component of the study, using econometric criteria (including choice probability,  
44 confidence level, accuracy level, attrition rate, and number of choice tasks), subgroups of more than  
45 30 individuals are required to conduct meaningful statistical analysis [43, 44]. Because the DCE  
46 study will undertake subgroup analysis on four to five groups (including respondent age group,  
47 socio-economic status, location of residence, experience with the GIFT device), up to 200  
48 participants per site will be recruited for the DCE study, with a quarter of the participants recruited  
49 on the diagnostic study of the GIFT device, and reminder from women coming for gynecological  
50 consultations at the study clinic.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 No sample size calculation is needed for the decision tree algorithm study, which is using data from  
3  
4 the diagnostic study. Equally, there are no sample size requirements for the economic evaluation.  
5  
6

### 7 *Study procedures and data collection*

#### 8 9 1) Diagnostic study

10  
11 The diagnostic study participant and sample flow from screening to laboratory results is described  
12 in Figure 1 and detailed in Supplementary Figure 1 - Diagnostic study flow steps. After  
13 confirmation that participants were eligible for the study (Table 2) and written informed consent  
14 obtained, enrolled women will be interviewed using a structured questionnaire with questions  
15 including demographics, sexual behaviour, hygiene habits, current medical and reproductive  
16 history, medication, and symptoms. The data will be captured on paper or electronic case report  
17 forms (CRFs) (Figure 1). The clinician, midwife, or study nurse will perform a physical  
18 examination including a pelvic examination, and will collect finger prick blood for HIV testing and  
19 vaginal swabs using regular flocked swabs (Copan, Italy) (Figure 1 and Supplementary Figure 1 -  
20 Diagnostic study flow steps).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 The first inserted swab will be eluted in buffer and the nozzle-sample (provided with the GIFT kit)  
36 will be applied to two prototype GIFT devices, one near the patient and the other in the laboratory  
37 (Figure 1). A second swab will serve for cytokine ELISA testing, and a third swab for pH testing  
38 using a pH indicator strip and to prepare a vaginal smear slide for BV (Figure 1). The next swabs  
39 will be collected and used for CT, NG and TV diagnosis in the laboratory, for reference STI testing  
40 including MG, quantitative NAAT of vaginal microbiome bacteria, the detection of *Candida sp* and  
41 Y chromosome for the presence of semen. The last two collected swabs will be used to characterise  
42 the vaginal microbiome by using 16S rRNA PCR and sequencing (Figure 1).  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 2) Integration into care study

55  
56 The integration study is composed of four activities aiming to understand how GIFT can be  
57 integrated into STI control (Figure 2).  
58  
59  
60

1  
2 For the qualitative study assessing the user-experience, usability, and acceptability of the GIFT  
3 device at the point of care, data will be collected through IDIs and FGDs. Target groups will be:  
4 HCPs at the health facilities; local or regional policymakers, programmers, other opinion leaders,  
5 and decision-makers; and women who are eligible for the diagnostic study (Table 2), but who are  
6 not part of the diagnostic study. HCP participants will be identified through the diagnostic study  
7 sites and will be contacted directly to ask if they would be interested in participating. Policymakers  
8 recommended for inclusion through snowball sampling will be contacted and asked if they would  
9 be interested in participating. All women presenting at the family planning service facilities for  
10 inclusion in the diagnostic study will be informed about the integration study. For the DCE, the  
11 study team will seek to recruit women participating and not-participating in the GIFT diagnostic  
12 study to explore heterogeneity in patient preferences for various STI attributes. For all population  
13 groups, those who agree to participate will provide written informed consent, separate from the  
14 diagnostic study.

15  
16 For the decision tree classification algorithm, data will be obtained from the diagnostic study  
17 participants, and no additional participants will be recruited. For the economic evaluation,  
18 healthcare professionals at health facilities involved in GIFT device implementation and able to  
19 complete timesheets will be recruited.

20  
21 For the user experience activity (Figure 2, activity 1), up to 10-12 IDIs and/or 1-3 FGDs will be  
22 conducted with policy makers, up to 8-10 IDIs and/or 3 FGDs will be conducted with HCPs, and up  
23 to 12-15 IDIs and/or 3 FGDs will be conducted with women. FGDs will include participatory tools,  
24 such as card mapping. The FGDs with HCPs may additionally include role plays of how the  
25 providers would discuss the GIFT device with women, and how providers would discuss GIFT  
26 device results and subsequent care and management with women. IDIs will explore more detailed  
27 personal perceptions of the potential structures of integration.

28  
29 User experience data (qualitative and FGDs) on the patient experience will help inform the  
30 development of attributes for the DCE (Figure 2, activity 2). The DCE aims to identify the relative

1 importance of factors influencing patient' preferences for the use of GIFT device. For the DCE  
2 study face-to-face interviews using a questionnaire will be conducted, with the questionnaire asking  
3 respondents to state preferences for hypothetical alternatives, each described by several attributes.  
4 A D-efficient design will be used to identify the choice tasks to present to respondents. Each choice  
5 task presents two STI screening test options that are defined using different levels of the attributes  
6 and then asks respondents to choose their preferred option, with an opt-out option available (to  
7 choose neither of the two options). The results of the DCE will inform the development of STI  
8 management algorithms that integrate the GIFT device, to increase the acceptability of the STI  
9 management programme.  
10

11 A decision tree will be developed to classify symptomatic and asymptomatic women using the  
12 following attributes: socio-demographic information, signs and symptoms, medical history, sexual  
13 behaviour, the GIFT output, and vaginal pH. Different classifications will be tested by varying the  
14 combinations of the attributes and the number of levels of the tree. The algorithm will be developed  
15 using a training dataset (data from previous studies). After the development of the algorithm based  
16 on the training dataset, the algorithm will be tested on the data to be collected in the diagnostic  
17 study and refined if necessary. The algorithm will be designed to be as simple as possible  
18 (minimum number of nodes and minimum number of scenarios) and usable in routine practice.  
19 Finally, the management outcomes will be compared to those obtained with the WHO  
20 recommendations.  
21

22 The economic evaluation (Figure 2, activity 4) will involve the collection of cost and service  
23 utilisation data from a provider's perspective at each of the clinical sites, using an ingredients-based  
24 approach. After obtaining approval from the facility and/or district, relevant facility management  
25 staff will be approached to share financial and other facility-level data. The cost and utilisation data  
26 will be collected from individual facility records and financial reports through cost data collection  
27 tools at each study site. The time that it takes to perform and analyse the GIFT assay will be  
28 obtained from clinical study staff. The time required for the delivery of routine family planning and  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 STI services will be assessed through timesheets completed by selected healthcare workers at the  
3  
4 study sites. These data will be captured in the Provider Cost Data Collection Tool by data  
5  
6 collectors. This activity will determine the cost and budget impact of the identified screening or  
7  
8 diagnostic algorithm with the GIFT device and will model the cost-effectiveness of the different  
9  
10 strategies of integration of GIFT into care.  
11  
12

### 13 14 *Laboratory procedures*

15  
16 The BV diagnosis will be obtained from a vaginal smear carried out with the third swab collected  
17  
18 during the gynecological examination (Figure 1). The slide will be transferred from the clinic to the  
19  
20 respective on-site laboratory for Gram staining and Nugent scoring [40].  
21  
22

23  
24 CT, NG, and TV diagnosis from collected vaginal swabs (Figure 1) will be performed using the  
25  
26 diagnostic tests available in each of the three sites. In South Africa and Zimbabwe, GeneXpert tests  
27  
28 (Cepheid, Sunnyvale, USA) will be used for CT and NG detection, and TV detection will be  
29  
30 performed with the OSOM trichomonas rapid test or TV GeneXpert test, depending on the  
31  
32 availability. In Madagascar, the vaginal swabs will be tested by UBEX (IPM) using validated qPCR  
33  
34 protocols for CT, NG, and TV detection [45,46].  
35  
36

37  
38 The swabs collected for STI reference testing in South Africa and Zimbabwe will be shipped to the  
39  
40 IPM (Madagascar) for reference testing using validated qPCR [45-47], vaginal bacteria-specific  
41  
42 quantitative qPCR testing, molecular detection of *Candida* spp. and presence of semen (Y  
43  
44 chromosome testing).  
45  
46

47  
48 Three swabs per participant will be sent to the University of Cape Town, for cytokine ELISA  
49  
50 measurement and 16S rRNA gene PCR and sequencing. The results obtained with the prototype  
51  
52 GIFT device will be compared to the cytokine concentrations resulting from the ELISA  
53  
54 measurements. 16S rRNA gene sequencing and *Candida* spp. NAAT will be used to evaluate the  
55  
56 proportion of cases of genital inflammation that could be explained by vaginal bacterial or fungal  
57  
58 dysbiosis, respectively. The swabs will be stored in each study site at -80°C until shipment using  
59  
60 dry ice to the respective laboratories as stipulated above.

### *Monitoring, quality assurance, and control*

This study will be monitored in accordance with regulations applicable to diagnostic study, including International Committee on Harmonisation of Good Clinical Practice (ICH-GCP) and GCLP (Good Clinical Laboratory Practices) requirements, and sponsor-specific standard operating procedures (SOP). The diagnostic study will be monitored by the Epidemiology and Clinical Research Unit at the IPM. Routine monitoring will be conducted throughout the study and at the study closure. All laboratory activities including specimen transport, processing, testing, result reporting, and storage will be conducted in accordance with clinical trial quality requirements. The GCLP guidelines will be followed and the designated laboratories will perform testing according to the SOPs which will be documented in the analytical plan.

A batch of known negative and positive specimens for CT/NG, TV, pregnancy test and slides for Nugent scoring will be provided by the UBEX laboratory at IPM for external quality control. The external quality control will consist of three panels to be tested at the start, middle, and end of the study or every three months. Prior to the use of the GIFT devices, a lot validation will be performed using the quality control panel provided by the manufacturer according to the SOP.

### *Data management*

The REDCap platform will be used as clinical data management system (CDMS) for the clinical study. Depending on the organisation in each study site data will be collected partially or fully using paper CRF (pCRF) before being entered into REDCap on a daily basis. In addition, data may be collected and entered in real-time into REDCap using tablets.

The GIFT database will be managed by the Epidemiology and Clinical Research Unit at the IPM. The quality and accuracy of CRF data transcription into the database will be verified weekly. Missing or overdue forms will be identified and tracked using the REDCap field comment log. A control script developed by the central data manager will check the double data entry, and any transcription differences found will be noted. Status reporting including the list of inconsistencies will be done weekly by the central data management team. The weekly reports will also resume the

1 progress of data collection and entry in each study site. All reports will be sent to the operational  
2 team for verification and correction of the data, if required.  
3

4 External data sources not described on the CRF like cytokine ELISA data, the STI reference testing  
5 data, and 16S rRNA sequencing data will be reconciled against the CDMS at the end of the study.  
6

7 For the user experience study, FGD and IDI data will be audio-recorded and electronically  
8 transcribed into the national and/or local language of the study sites. The DCE questionnaire data  
9 will be captured electronically using REDcap and securely stored on a password-protected  
10 computer. Data for the economic evaluation will be collected in a Provider Cost: Data Collection  
11 Tool, and timesheets will be completed in Excel by HCPs.  
12

## 13 **Data analysis**

### 14 *Diagnostic study*

15 1) Primary analysis: Sensitivity and specificity estimated of the GIFT device with 95% confidence  
16 intervals using any positive etiological NAATs for STIs (CT, NG, TV and MG) or Nugent score  
17 result for BV as reference standards will be calculated. Visual readings of the GIFT device  
18 performed by the clinicians and technicians will be included separately in this analysis.  
19

20 2) Secondary analysis: Positive and negative predictive values with 95% confidence intervals of the  
21 GIFT device will be compared with the likelihood ratios using NAAT and Nugent scoring as  
22 reference standards overall and in each country (which may have different STI prevalence that will  
23 impact these predictive values).  
24

25 The performance of the GIFT device will be compared to the performance of syndromic  
26 management for detecting STIs. Both methods (GIFT and syndromic management) will be  
27 compared to any positive results of NAAT (for CT, NG, TV and MG) and/or BV detected by  
28 Nugent scoring.  
29

30 Agreement between the GIFT device results read visually by both the clinician and the laboratory  
31 technician and on an automated reader will be determined.  
32



1  
2 The concordance of band intensity results from the GIFT device and cytokine ELISA measurements  
3  
4 will be analysed. This analysis will be used to optimize the cytokine concentration cut-offs for  
5  
6 interpretation of the GIFT device performance, in terms of sensitivity, specificity, and predictive  
7  
8 values.  
9

10  
11 The impact of additional characteristics and/or determinants (such as intermediate microbiota,  
12  
13 Candida, age, parity, and sexual activity) on the prediction of STI/BV status in women and the  
14  
15 impact on the accuracy of the device will be determined.  
16

### 17 18 *Integration into care study*

19  
20  
21 For the user experience study, iterative thematic analysis will be applied to the IDI and FGD data,  
22  
23 conducted by the qualitative research team. Sekhon's framework of acceptability of healthcare  
24  
25 interventions will be used [48].  
26  
27

28  
29 For the DCE, data will be analysed in STATA using the utility function modelled from two  
30  
31 alternatives: a systematic (explainable) component and a random (unexplainable) component. To  
32  
33 estimate the trade-offs that respondents are willing to make between attributes, willingness to pay  
34  
35 (WTP) for marginal improvements in attributes will be estimated for all attributes. WTP estimates  
36  
37 will be calculated as the ratio of the coefficient of interest to the negative of the coefficient on the  
38  
39 attribute with continuous variables. Subgroup analyses will be undertaken to investigate how  
40  
41 preferences are influenced by demographic characteristics, residential area, socio-economic status,  
42  
43 and experience of point-of-care testing.  
44  
45

46  
47 The assessment of the decision tree classification algorithm will be based on the accuracy of the  
48  
49 classification compared to the results of the gold standard methods (NAATs and Nugent score).  
50  
51 Following this classification, different scenarios of management will be tested: immediate  
52  
53 treatment, referral, re-evaluation, and no treatment. These scenarios will be optimised in order to  
54  
55 avoid undertreatment and overtreatment by also considering immediate specific rapid diagnosis  
56  
57 tests (if available) or risk scores for immediate presumptive treatment.  
58  
59  
60

1  
2 For the economic evaluation, models will be developed in Microsoft Excel. For the cost analysis, an  
3  
4 ingredient-based model will be constructed, and for the budget impact analysis, an expenditure-  
5  
6 based model will be applied. A decision-analysis model to estimate the cost and health outcomes  
7  
8 associated with different GIFT device implementation strategies will be developed. The main  
9  
10 outcome will measure the effectiveness of each approach in correctly diagnosing an STI and/or BV  
11  
12 in women, proxied by the sensitivity measure of the diagnostic test or approach, in comparison to  
13  
14 the gold standard NAATs and Nugent scoring. Secondary outcomes such as the performance of the  
15  
16 device versus syndromic management and the variation in device results when determined by a  
17  
18 clinician, laboratory technician or an automated reader, will be assessed by means of scenario  
19  
20 analyses. Univariate sensitivity analyses will be carried out to test the robustness of the findings.  
21  
22  
23  
24  
25  
26  
27

### 28 **Patient and public involvement**

29  
30  
31 Patients or the public were not involved in the formulation of the research question, study design,  
32  
33 recruitment of the study. Findings will be reported to participating families and collaborators at the  
34  
35 end of the study.  
36  
37  
38  
39  
40  
41

### 42 **Ethics and dissemination**

43  
44 The study will be carried out according to the principles stated in the Declaration of Helsinki (as  
45  
46 amended in Seoul in 2008) and any further updates, all applicable national and international  
47  
48 regulations, and according to the most recent applicable principles of the GCP-ICH E6. All the  
49  
50 participants will be informed about the diagnostic results. The choice of treatment for STIs or BV  
51  
52 will be based on the current national guidelines in the three study sites.  
53  
54 The protocol and all study documents such as informed consent forms were reviewed and approved  
55  
56 by the University of Cape Town Human Research Ethics Committee (HREC reference 366/2022),  
57  
58 Medical Research Council of Zimbabwe (MRCZ/A/2966), Comité d’Ethique pour la Recherche  
59  
60

1  
2 Biomédicale de Madagascar (N° 143 MNSAP/SG/AMM/CERBM) and the London School of  
3  
4 Hygiene and Tropical Medicine ethics committee (LSHTM reference 28046).  
5

6  
7 Prior to the start, this study has been submitted to the Clinicaltrials.gov public registry  
8  
9 (NCT05723484).  
10

## 11 12 13 14 15 **Discussion**

16  
17  
18 Here, we have described the diagnostic and integration studies that will be used to validate the  
19  
20 GIFT device as a proof-of-principle prototype for implementing a novel POC cytokine test to detect  
21  
22 vaginal inflammation associated with STIs and/or BV among women in differing clinical settings.  
23  
24

25  
26 The development of low-cost rapid POC tests has become a major focus in the management of  
27  
28 STIs/BV to replace or improve syndromic management widely adopted in Africa. The availability  
29  
30 of these tests would offer all sexually active women the opportunity to be screened and treated. This  
31  
32 may have particular benefit to women at high risk of STIs, including young women, pregnant  
33  
34 women, female sex workers, and those with HIV.  
35  
36

37  
38 The results from the prospective diagnostic study will be closely combined with the results of the  
39  
40 qualitative research, modeling, and economic evaluation. The feasibility and acceptability studies  
41  
42 will inform how the GIFT device could be integrated into national guidelines. The GIFT feasibility  
43  
44 study consists of a “user experience and GIFT perceptions” prototype involving a large spectrum of  
45  
46 people selected from the general population (HCPs, sexually active women, policymakers) that will  
47  
48 help extend STI/BV screening into family planning services in primary health care services at  
49  
50 affordable costs for LMICs, with the aim that women should know about their health without  
51  
52 delaying their treatment. The qualitative part of the study will improve our understanding of the  
53  
54 different key factors contributing to the successful implementation of a novel screening device for  
55  
56 STIs and BV in LMICs.  
57  
58  
59  
60

1  
2 Besides evaluating a POC test for screening of STIs and BV, this study will be among the first of its  
3  
4 kind, focusing on STI/BV prevalence and risk factors including up to 675 women mainly from  
5  
6 urban areas in three sub-Saharan countries in different STI/BV contexts. The GIFT study will also  
7  
8 improve our knowledge in both biological and molecular characterisation of the three most common  
9  
10 STIs (CT, NG, and TV) and MG in association with the different states of the vaginal microbiota  
11  
12 and will provide new insights into the interplay between STI and BV.  
13  
14  
15

16  
17 Our study protocol has some limitations. First of all, the user evaluation of the GIFT device,  
18  
19 evaluating the performance of the device when applied by different types of users, does not include  
20  
21 the evaluation of the extraction step. The extraction step of the vaginal swab will be performed by  
22  
23 the medical staff only and not in parallel with a duplicate vaginal swab by a laboratory professional.  
24  
25 Secondly, due to budget constraints, the STI diagnostic testing in Madagascar will be conducted by  
26  
27 batch testing in the laboratory and not by POC NAAT testing as will be done in South Africa and  
28  
29 Zimbabwe. Consequently, Malagasy participants will receive their results and treatment, if needed,  
30  
31 after a delay of up to 10 days. This delay in treatment may facilitate further STI transmission.  
32  
33 However, the study clinician may decide on presumptive treatment in alignment with the routine  
34  
35 care practice in place.  
36  
37  
38  
39

40  
41 In conclusion, the multidisciplinary study will be instrumental in developing strategies to improve  
42  
43 STI and BV management in LMICs.  
44  
45

#### 46 **Study status**

47  
48 The study is ongoing. Data collection and data analysis are ongoing.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **DECLARATIONS**

### **Consent for publication**

Not applicable

### **Availability of data and materials**

Not applicable. The study is ongoing. Data collection and data analysis are ongoing.

### **Competing interests**

The last authors, Jo-Ann Passmore and Lindi Masson, declare sharing a patent for the biomarkers for GIFT: patent number PCT/IB 2014/065740, October 2014. All other authors declared no potential conflict of interest.

### **Author Statement**

SR and TC wrote the first draft of the manuscript. LM designed Figure 1, EHE and SF designed Figure 2. All authors contributed to the writing, and reviewed and approved the manuscript. LM and JAP validated the final version. All authors contributed to the elaboration of the study protocol.

GIFT study group: Eneyi Kpokiri<sup>1</sup>, Bahiah Meyer<sup>2</sup>, Phumla Radebe<sup>2</sup>, Conita Lombard<sup>2</sup>, Celia Mehoul-Loko<sup>2</sup>, Yacoeb Ganief<sup>2</sup>, Rezeen Daniels<sup>3</sup>, Anda Madikida<sup>3</sup>, Karabo Mahlangu<sup>3</sup>, Tinashe Mwaturura<sup>4,5</sup>, Mutsawashe Chisenga<sup>4,5</sup>, Joseph F Chipanga<sup>4,5</sup>, Tsitsi Bandason<sup>4,5</sup>, Patricia Makunyire<sup>4,5</sup>, Felicia Mhangami<sup>4,5</sup>, Jayjay Karumazondo<sup>5</sup>, Jason Naidoo<sup>5</sup>, Karen Webb<sup>4</sup>, Lyndon Mungur<sup>6</sup>, Ashley Uys<sup>6</sup>, Darryl Uys<sup>6</sup>, Elise Smith<sup>7</sup>, Saberi Marias<sup>8</sup>, Solange Rasoanandrianina<sup>9</sup>, Dimitri Ravoavison<sup>9</sup>, Patrick Andry Rakotonirina<sup>9</sup>, Andrilaina Razakarivony<sup>9</sup>, Hantamalala Randria<sup>9</sup>, Alphonsine Rahantarimalala<sup>9</sup>, Lala Rafetrarivony<sup>10</sup>, Barivola Bernardson<sup>10</sup>, Tsiry

1  
2 Rasolofomanana<sup>10</sup>, Norohasina Randriamange<sup>10</sup>, Antsanirina Nomenjanahary<sup>10</sup>, Laurah  
3  
4 Rabarisoa<sup>10</sup>, Dimitri Rasoloson<sup>10</sup>, Sahara Raveloson<sup>10</sup>, Laura Randrianantenaina<sup>10</sup>, Hanitratiavina  
5  
6 Rakotonindriana<sup>10</sup>, Fenosoa Voanarivolalao<sup>10</sup>, Vaomalala Ranarinandra<sup>10</sup>, Farai Machinga<sup>11</sup>  
7  
8  
9

10  
11 <sup>1</sup> London School of Hygiene & Tropical Medicine, United Kingdom  
12

13 <sup>2</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa  
14

15 <sup>3</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa  
16

17 <sup>4</sup> Organization for Public Health Interventions and Development, Zimbabwe  
18

19 <sup>5</sup> The Biomedical Research and Training Institute, Zimbabwe  
20

21 <sup>6</sup> Medical Diagnostech, Cape Town, South Africa  
22

23 <sup>7</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
24  
25 Town, South Africa  
26

27 <sup>8</sup> Research Contracts and Innovation, University of Cape Town, South Africa  
28

29 <sup>9</sup> Centre Hospitalier Universitaire de Gynécologie et Obstétrique de Befelatanana, Antananarivo,  
30  
31 Madagascar  
32

33 <sup>10</sup> Institut Pasteur de Madagascar, Madagascar  
34

35 <sup>11</sup> National Family Planning Council, Zimbabwe  
36  
37  
38  
39  
40  
41  
42

### 43 **Funding**

44  
45 The study is funded by the EDCTP through the EDCTP2 programme supported by the European  
46  
47 Union (grant number EDCTP-RIA2020I-3297-GIFT). The views and opinions of authors expressed  
48  
49 herein do not necessarily state or reflect those of EDCTP.  
50  
51  
52  
53  
54  
55  
56  
57

### 58 **References**

59  
60

- 1  
2 1. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM,  
3 Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N, Taylor MM. Chlamydia, gonorrhoea,  
4 trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. *Bull World Health*  
5 *Organ*. 2019 Aug 1;97(8):548-562P. doi: 10.2471/BLT.18.228486.  
6  
7  
8  
9
- 10  
11 2. Tuddenham S, Ravel J, Marrazzo JM. Protection and Risk: Male and Female Genital Microbiota  
12 and Sexually Transmitted Infections. *J Infect Dis*. 2021;223 (12 Suppl 2):S222-S235. doi:  
13 10.1093/infdis/jiaa762.  
14  
15
- 16  
17 3. Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female  
18 reproductive health. *Nat Microbiol*. 2022;7(8):1116-1126. doi: 10.1038/s41564-022-01177-x.  
19  
20
- 21  
22 4. Ness RB, Hillier S, Richter HE, Soper DE, Stamm C, Bass DC, Sweet RL, Rice P. Can known  
23 risk factors explain racial differences in the occurrence of bacterial vaginosis? *J Natl Med Assoc*.  
24 2003;95(3):201-12.  
25  
26  
27
- 28  
29 5. Yotebieng M, Turner AN, Hoke TH, Van Damme K, Rasolofomanana JR, Behets F. Effect of  
30 consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status.  
31 *Trop Med Int Health*. 2009;14(4):480-6. doi: 10.1111/j.1365-3156.2009.02235.x.  
32  
33  
34
- 35  
36 6. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a  
37 systematic review. *Am J Obstet Gynecol*. 2013;209:505–23.  
38  
39
- 40  
41 7. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N,  
42 Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW,  
43 Ndung'u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. Cervicovaginal bacteria are a major  
44 modulator of host inflammatory responses in the female genital tract. *Immunity*. 2015;42(5):965-  
45 76. doi: 10.1016/j.immuni.2015.04.019.  
46  
47  
48
- 49  
50 8. Jespers V, van de Wijgert J, Cools P, Verhelst R, Verstraelen H, Delany-Moretlwe S, Mwaura M,  
51 Ndayisaba GF, Mandaliya K, Menten J, Hardy L, Crucitti T; Vaginal Biomarkers Study Group. The  
52 significance of *Lactobacillus crispatus* and *L. vaginalis* for vaginal health and the negative effect of  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2 recent sex: a cross-sectional descriptive study across groups of African women. *BMC Infect Dis.*  
3  
4 2015;15:115. doi: 10.1186/s12879-015-0825-z.  
5  
6  
7 9. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ. Understanding vaginal microbiome  
8  
9 complexity from an ecological perspective. *Transl Res.* 2012;160(4):267-82. doi:  
10  
11 10.1016/j.trsl.2012.02.008.  
12  
13  
14 10. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs  
15  
16 of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. *Sex Transm Dis.* 2019;46(5):304-  
17  
18 311. doi: 10.1097/OLQ.0000000000000972.  
19  
20  
21 11. Adapen C, Réot L, Menu E. Role of the human vaginal microbiota in the regulation of  
22  
23 inflammation and sexually transmitted infection acquisition: Contribution of the non-human  
24  
25 primate model to a better understanding? *Front Reprod Health.* 2022;4:992176. doi:  
26  
27 10.3389/frph.2022.992176.  
28  
29  
30 12. Kyongo JK, Crucitti T, Menten J, Hardy L, Cools P, Michiels J, Delany-Moretlwe S, Mwaura  
31  
32 M, Ndayisaba G, Joseph S, Fichorova R, van de Wijgert J, Vanham G, Ariën KK, Jespers V. Cross-  
33  
34 Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal  
35  
36 Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention. *Clin*  
37  
38 *Vaccine Immunol.* 2015;22(5):526-38. doi: 10.1128/CVI.00762-14.  
39  
40  
41 13. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the Vaginal Microbiome Alter  
42  
43 the Innate Immune Response and Barrier Properties of the Human Vaginal Epithelia in a Species-  
44  
45 Specific Manner. *J Infect Dis.* 2014;209 (12):1989–99. doi: 10.1093/infdis/jiu004  
46  
47  
48 14. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, Gamielidien H, Williamson  
49  
50 C, Mckinnon LR, Walzl G, Karim QA. Defining genital tract cytokine signatures of sexually  
51  
52 transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-  
53  
54 sectional study. *Sex Transm infect.* 2014;90(8):580-7.  
55  
56  
57  
58  
59  
60



- 1  
2 15. Mtshali A, Ngcapu S, Mindel A, Garrett N, Liebenberg L. HIV susceptibility in women: The  
3  
4 roles of genital inflammation, sexually transmitted infections and the genital microbiome. *J Reprod*  
5  
6 *Immunol.* 2021;145:103291. doi: 10.1016/j.jri.2021.103291.  
7  
8  
9 16. Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, Gamiieldien H, Ngcapu S,  
10  
11 Johnson L, Lauffenburger DA, Abdool Karim Q, Abdool Karim SS, Passmore JA. Inflammatory  
12  
13 cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and  
14  
15 bacterial vaginosis who are at high risk of HIV infection. *Sex Transm Infect.* 2016;92(3):186-93.  
16  
17  
18 17. Filardo S, Di Pietro M, Tranquilli G, Latino MA, Recine N, Porpora MG, Sessa R. 2019.  
19  
20 Selected immunological mediators and cervical microbial signatures in women with *Chlamydia*  
21  
22 *trachomatis* infection. *mSystems* 4:e00094-19. <https://doi.org/10.1128/mSystems.00094-19>.  
23  
24  
25 18. Jespers V, Kyongo J, Joseph S, Hardy L, Cools P, Crucitti T, Mwaura M, Ndayisaba G, Delany-  
26  
27 Moretlwe S, Buyze J, Vanham G. A longitudinal analysis of the vaginal microbiota and vaginal  
28  
29 immune mediators in women from sub-Saharan Africa. *Sci. Rep.* 2017;7(1):1-3.  
30  
31  
32 19. Masson L, Barnabas S, Deese J, Lennard K, Dabee S, Gamiieldien H, Jaumdally SZ, Williamson  
33  
34 AL, Little F, Van Damme L, Ahmed K. Inflammatory cytokine biomarkers of asymptomatic  
35  
36 sexually transmitted infections and vaginal dysbiosis: a multicentre validation study. *Sex Transm*  
37  
38 *Infect.* 2019;95(1):5-12.  
39  
40  
41 20. Galvin SR and Cohen MS. The role of sexually transmitted diseases in HIV transmission. *Nat*  
42  
43 *Rev Microbiol.* 2004;2(1):33-42. doi: 10.1038/nrmicro794.  
44  
45  
46 21. Borgdorff H, Tsvitvadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Schuren FH,  
47  
48 van de Wijgert JH. Lactobacillus-dominated cervicovaginal microbiota associated with reduced  
49  
50 HIV/STI prevalence and genital HIV viral load in African women. *ISME J.* 2014;8(9):1781-93. doi:  
51  
52 10.1038/ismej.2014.26.  
53  
54  
55 22. Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little  
56  
57 F, Mansoor LE, Naranbhai V, Lauffenburger DA. Genital inflammation and the risk of HIV  
58  
59 acquisition in women. *Clin. Infect. Dis.* 2015;61(2):260-9.  
60

- 1  
2 23. McClelland RS, Lingappa JR, Srinivasan S, Kinuthia J, John-Stewart GC, Jaoko W, et al.  
3  
4 Evaluation of the association between the concentrations of key vaginal bacteria and the increased  
5  
6 risk of HIV acquisition in african women from five cohorts: a nested case-control study. *Lancet*  
7  
8 *Infect Dis.* 2018;18:554–64. doi: 10.1016/S1473-3099(18)30058-6  
9  
10  
11 24. Jarrett OD, Srinivasan S, Richardson BA, Fiedler T, Wallis JM, Kinuthia J, et al. Specific  
12  
13 vaginal bacteria are associated with an increased risk of trichomonas vaginalis acquisition in  
14  
15 women. *J Infect Dis.* 2019;220:1503–10. doi: 10.1093/infdis/jiz354.  
16  
17  
18 25. McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis:  
19  
20 implications for HIV transmission. *AIDS Res Hum Retroviruses* **2019**; 35:219–28.  
21  
22  
23 26. GBD 2015 HIV collaboarators, *Lancet HIV* 2016; 3: e361–87. [http://dx.doi.org/10.1016/](http://dx.doi.org/10.1016/S2352-3018(16)30087-X)  
24  
25 [S2352-3018\(16\)30087-X](http://dx.doi.org/10.1016/S2352-3018(16)30087-X).  
26  
27  
28 27. Fettweis JM, Serrano MG, Brooks JP, Edwards DJ, Girerd PH, Parikh HI, et al. The Vaginal  
29  
30 Microbiome and Preterm Birth. *Nat Med.* 2019;25(6):1012–21. doi: 10.1038/s41591-019-0450-2.  
31  
32  
33 28. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World  
34  
35 Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.  
36  
37  
38 29. Verwijs MC, Agaba SK, Sumanyi JC, Umulisa MM, Mwambarangwe L, Musengamana V,  
39  
40 Uwineza M, Cuylaerts V, Crucitti T, Jespers V, Van De Wijgert JH. Targeted point-of-care testing  
41  
42 compared with syndromic management of urogenital infections in women (WISH): a cross-  
43  
44 sectional screening and diagnostic accuracy study. *Lancet Infect Dis.* 2019;19(6):658-69.  
45  
46  
47 30. Garrett N, Mtshali A, Osman F, Masson L, McKinnon LR, Singh R, Mitchev N, Ngobese H,  
48  
49 Kharsany ABM, Abdool Karim S, Mlisana K, Passmore JA, Rompalo A, Mindel A, Liebenberg L.  
50  
51 Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial  
52  
53 vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. *Sex*  
54  
55 *Transm Infect.* 2021;97(8):555-565. doi: 10.1136/sextrans-2020-054740.  
56  
57  
58 31. Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, Andriesen J, Osman F, Ngcapu  
59  
60 S, Vandormael A, Mindel A, Abdool Karim SS, Bekker LG, Gray G, Corey L, Tomita A, Garrett

- 1  
2 N. Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South  
3 Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial. *Clin Infect*  
4 *Dis.* 2023;76(5):881-889. doi: 10.1093/cid/ciac824. Erratum in: *Clin Infect Dis.* 2023;76(1):182.  
5  
6  
7  
8  
9 32. Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-Care Testing for Sexually Transmitted  
10 Infections: A Review of Recent Developments. *Arch Pathol Lab Med.* 2020;144(11):1344-1351.  
11  
12  
13 33. The diagnostics landscape for sexually transmitted infections. Geneva: World Health  
14 Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.  
15  
16  
17  
18 34. Land, K.J., Boeras, D.I., Chen, X.S. *et al.* REASSURED diagnostics to inform disease control  
19 strategies, strengthen health systems and improve patient outcomes. *Nat Microbiol* 4, 46–54 (2019).  
20  
21 <https://doi.org/10.1038/s41564-018-0295-3>  
22  
23  
24  
25 35. Torrone EA, Morrison CS, Chen P-L, Kwok C, Francis SC, Hayes RJ, et al. (2018) Prevalence  
26 of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An  
27 individual participant data meta-analysis of 18 HIV prevention studies. *PLoS Med.* 2018;15(2):  
28 e1002511.  
29  
30  
31  
32  
33  
34 36. Wand H, Reddy T, Dassaye R, Moodley J, Naidoo S, Ramjee G. Estimating prevalence and  
35 incidence of sexually transmitted infections among South African women: Implications of  
36 combined impacts of risk factors. *Int J STD AIDS.* 2020;31(11):1093-1101. doi:  
37 10.1177/0956462420915388.  
38  
39  
40  
41  
42  
43 37. Delany-Moretlwe S, Mgodhi N, Bekker L, et al. High prevalence and incidence of gonorrhoea  
44 and chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and  
45 Zimbabwe: results from the HPTN 082 trial. *Sex Transm Infect.* 2023;99:433-439.  
46  
47  
48  
49  
50 38. Behets F, Andriamiadana J, Rasamilalao D, Ratsimbazafy N, Randrianasolo D, Dallabetta G,  
51 Cohen M. Sexually transmitted infections and associated socio-demographic and behavioural  
52 factors in women seeking primary care suggest Madagascar's vulnerability to rapid HIV spread.  
53  
54  
55  
56  
57 *Trop Med Int Health.* 2001;6(3):202-11.  
58  
59  
60

- 1  
2 39. Country factsheets, UNAIDS 2023.  
3  
4 <https://www.unaids.org/en/regionscountries/countries/madagascar>.  
5  
6 40. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis improved by a  
7  
8 standardized method of gram stain interpretation. *J Clin Microbiol*. 1991;29:297e301.  
9  
10 41. Dworkin, S.L. specimen Size Policy for Qualitative Studies Using In-Depth Interviews. *Arch*  
11  
12 *Sex Behav* 2012; 41, 1319–1320.  
13  
14 42. Guest G, Namey E, McKenna K. How Many Focus Groups Are Enough? Building an Evidence  
15  
16 Base for Nonprobability specimen Sizes. *Field Methods*. 2017;29(1):3-22.  
17  
18 43. Louviere J, Hensher D, Swait J: *Stated Choice Methods: Analysis and Application*, First edition  
19  
20 edn. Cambridge, United Kingdom: Cambridge University Press; 2000.  
21  
22 44 Ryan M, Gerard K, Amaya-Amaya M (eds.): *Using Discrete Choice Experiments to Value*  
23  
24 *Health and Health Care*. Dordrecht, the Netherlands: Springer; 2008.  
25  
26 45. PRESTO CT/NG combined qualitative real time CT/NG assay (Kit # GM CG 160500). Goffin  
27  
28 Molecular Technologies, the Netherlands  
29  
30 46. Crucitti T, Van Dyck E, Tehe A, Abdellati S, Vuylsteke B, Buve A, Laga M. Comparison of  
31  
32 culture and different PCR assays for detection of *Trichomonas vaginalis* in self collected vaginal  
33  
34 swab specimens. *Sex Transm Infect*. 2003 Oct;79(5):393-8. doi: 10.1136/sti.79.5.393. PMID:  
35  
36 14573835; PMCID: PMC1744760.  
37  
38 47. Müller EE, Venter JM, Magooa MP, Morrison C, Lewis DA, Mavedzenge SN. Development of  
39  
40 a rotor-gene real-time PCR assay for the detection and quantification of *Mycoplasma genitalium*. *J*  
41  
42 *Microbiol Methods*. 2012 Feb;88(2):311-5. doi: 10.1016/j.mimet.2011.12.017. Epub 2011 Dec 29.  
43  
44 PMID: 22230235.  
45  
46 48. Sekhon, M., Cartwright, M. & Francis, J.J. Acceptability of healthcare interventions: an  
47  
48 overview of reviews and development of a theoretical framework. *BMC Health Serv Res*. 2017;17,  
49  
50 88. <https://doi.org/10.1186/s12913-017-2031-8>.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Acknowledgements

We thank in advance all women who will participate in this study and the healthcare workers who will be involved in the recruitment and enrolment of the study participants.

We would also like to thank EDCTP and the members of GIFT study group for making this study possible. We thank the members of the community advisory boards for their valuable advice.

We are extremely grateful to the members of the scientific advisory board for the precious scientific discussions and suggestions for improving our study.

## Figure Legend

### Figure 1: Schematic of the GIFT diagnostic study

The recruited women who meet the inclusion criteria and consent to participate in the GIFT study will be administered a questionnaire. Data will be recorded on case report forms (CRF) in a paper or electronic (tablet) format by the clinical nurse followed by a gynecological exam. Vaginal swabs are collected: the first collected swab will be used for two GIFT assays: the first GIFT will be performed at the bedside by the midwife/nurse and the second GIFT by the lab technician. Each of them will read visually their own performed GIFT (naked eye reading). The two respective GIFT assays will then be read using a lateral flow automated reader. The other collected swabs will be used for different laboratory assays for the evaluation of the GIFT performance. HIV testing on fingerpick blood will be also included at the end of the medical exam. The figure was created with BioRender.

### Figure 2: Integration study activities

Description of the four activities that will be performed for the GIFT integration into care study for improving the STI/BV diagnosis and control in women: 1) user experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews with key

1  
2 stakeholders, 2) discrete choice experiments, 3) development of a decision tree classification  
3  
4 algorithm and 4) economic evaluation of defined management algorithms. In addition to the women  
5  
6 already participating to the GIFT diagnostic study, health care professionals (HCP), policy makers,  
7  
8 key opinion leaders and patients coming for consultation will be included in the study.  
9


## 10 11 **Additional files**

### 12 **Supplementary Figure 1: Diagnostic study flow steps**

13  
14  
15  
16 Description: Women attending family planning services will receive explanations on the GIFT  
17  
18 study. After written consent and validation of the eligibility criteria and written informed consent,  
19  
20 the enrolled woman will be subjected to a structured questionnaire. The data will be captured on  
21  
22 paper or electronic case report form (CRF) by the clinical nurse. The CRF consists of 8 modules  
23  
24 that will include all the information from sociodemographic information, behavioral risk assessment  
25  
26 to medical information collected during the gynecological examination by the midwife or nurse.  
27  
28

29  
30 Each CRF assigned to each participant will contain all the data collected through the diagnostic  
31  
32 study including laboratory results that will be recorded in the REDCap GIFT database.  
33  
34

35 The vaginal swab sample collection will be done by the midwife/nurse after gynecological  
36  
37 examination for : GIFT assays, pH measurement and microscopic analysis of a vaginal smear slide  
38  
39 for BV diagnosis, and STI diagnosis. For this latter, a couple of vaginal swabs will be used for  
40  
41 nucleic-acid amplification tests (NAAT) for CT, NG and TV to be performed locally on each study  
42  
43 site. Based on the on-site positive diagnostic results for CT, NG, TV and BV a treatment will be  
44  
45 offered by the clinic or hospital clinician to the participant. HIV will be tested on fingerprick blood.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



The recruited women who meet the inclusion criteria and consent to participate in the GIFT study will be administered a questionnaire. Data will be recorded on case report forms (CRF) in a paper or electronic (tablet) format by the clinical nurse followed by a gynecological exam. Vaginal swabs are collected: the first collected swab will be used for two GIFT assays: the first GIFT will be performed at the bedside by the midwife/nurse and the second GIFT by the lab technician. Each of them will read visually their own performed GIFT (naked eye reading). The two respective GIFT assays will then be read using a lateral flow automated reader. The other collected swabs will be used for different laboratory assays for the evaluation of the GIFT performance. HIV testing on fingerpick blood will be also included at the end of the medical exam. The figure was created with BioRender.

645x452mm (118 x 118 DPI)

## USER EXPERIENCES AND GIFT PERCEPTIONS

- **Research questions**
  - how HCPs would use the GIFT device?
  - where the GIFT device would be placed within a health facility
  - how it would fit into the clinic flow?
  - What are the setting-specific barriers to and facilitators of using the GIFT device for the patient?
  - What counseling advice would be needed when using the GIFT device?
- **Target groups**
  - Health care professionals
  - Policy makers
  - Key opinion leaders
  - Patients

## DISCRETE CHOICE EXPERIMENTS (DCE)

- **Research questions**
  - What are the user (patient) preferences for a patient management algorithm?
  - What is the preference heterogeneity across users?
  - Willingness to pay?
- **Target groups**
  - Women participant to the diagnostic study
  - Women non included in the diagnostic study

## DECISION TREE

- **Research questions**
  - What is the risk profile of women who test positive on the GIFT test?
  - How do different testing strategies (immediate treatment after GIFT positive vs further re-evaluation) affect outcomes?
  - If immediate treatment, which treatment would yield the best outcome?

## ECONOMIC EVALUATION

- **Research questions**
  - What are the costs and budget impact of the identified screening or diagnostic algorithm with the GIFT device?
  - What are the costs of the different algorithms and strategies for GIFT device integration?

**INTEGRATION OF GIFT  
INTO STI/BV CONTROL**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## SCREENING

Explanation about the study to women attending family planning

## CONSENT

- Verification of inclusion / exclusion criteria
- Consent signature
- Collection of urine sample for pregnancy test

## DATA COLLECTION

Questionnaire : **Case Report Form (CRF)**

- Module 1 : Screening and Enrollment
- Module 2 : Sociodemographic Information
- Module 3 : Behavioral Risk Assessment
- Module 4 : General health and medical history including medication, smoke and alcohol
- Module 5 : Pregnancy and Contraception History
- Module 6 : HIV testing/status and treatment
- Module 7 : Gynaecological Physical Exam
- Module 8 : Sample collection and results

## SAMPLE COLLECTION

- Vaginal swabs sample collection
- pH and smear slide
- GIFT Test near the patient
- Finger prick blood sample collection for HIV test

## LABORATORY ANALYSIS

- GIFT test in the laboratory -Test reading using a lateral flow test automated reader
- STI/BV tests : NAAT for CT/NG/TV
- Nugent scoring
- HIV test

## LABORATORY RESULTS

- Treatment according syndromic approach OR appreciation of clinician
- Treatment of the participant and partners
- If positive HIV test : refer the participant to clinician

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any prespecified hypotheses	8-10
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	11
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	1-13
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	13-15
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	20-23
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	16-19
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	15
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	NA
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	NA
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	NA
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	NA
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	NA
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA

		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	NA
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	NA
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	NA
Generalisability	21	Discuss the generalisability (external validity) of the study results	NA
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## A Novel Point-Of-Care Cytokine Biomarker Lateral Flow Test for the Screening for Sexually Transmitted Infections and Bacterial Vaginosis: Study Protocol of a Multi-Centre Multi-Disciplinary Prospective Observational Clinical Study to Evaluate the Performance and Feasibility of the Genital Inflammation Test (GIFT).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-084918.R1
Article Type:	Protocol
Date Submitted by the Author:	29-Mar-2024
Complete List of Authors:	<p>RAMBOARINA, Stephanie; Institut Pasteur de Madagascar, Unit of Experimental Bacteriology  Crucitti, Tania; Institut Pasteur de Madagascar, Experimental Bacteriology Unit  Gill, Katherine ; University of Cape Town, IDDM; Desmond Tutu HIV Foundation  Bekker, Linda Gail; Desmond Tutu HIV Foundation; University of Cape Town, IDDM  Harding-Esch, Emma; London School of Hygiene and Tropical Medicine van de Wiggert, Janneke H.H.M.; University Medical Centre Utrecht, Julius Center for Health Sciences and Primary Care  Huynh, Bich-Tram; Pasteur Institute,  Fortas, Camille; Pasteur Institute  Harimanana, Aina; Institut Pasteur de Madagascar  Mayouya Gamana, Théodora; Institut Pasteur de Madagascar  Randremarana, Rindra Vatosoa; Institut Pasteur de Madagascar, Epidemiology Unit  Mangahasimbola, Reziky; Institut Pasteur de Madagascar  Dziva Chikwari, Chido; London School of Hygiene &amp; Tropical Medicine; Organization for Public Health Interventions and Development  Kranzer, Katharina; London School of Hygiene and Tropical Medicine, Clinical Research Department; Medical Center of the University of Munich, Division of Infectious Diseases and Tropical Medicine  Mackworth-Young , Constance ; London School of Hygiene and Tropical Medicine  Bernays , Sarah; The University of Sydney, School of Public Health; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, Global Health and Development  Thomas, Nicola; Desmond Tutu HIV Foundation; University of Cape Town  Anderson, David; Burnet Institute,  Tanko, Fatime; University of Cape Town, Division of Medical Virology; MRC, Institute of Medical Research and Medicinal Plant Studies  Manhanzva, Monalisa; University of Cape Town, IDDM; Centre for the Aids Programme of Research in South Africa  Lurie, Micaela; University of Cape Town, Division of Virology ; University</p>

	of Cape Town, IDDM Khumalo, Fezile; University of Cape Town, IDDM; Centre for the Aids Programme of Research in South Africa Sinanovic, Edina; University of Cape Town, Health Economic Unit, School of Public Health, Faculty of Health Sciences Honda, Ayako; Hitotsubashi University, Research Center for Health Policy and Economics Pidwell, Tanya; University of Cape Town, IDDM Francis, Suzanna ; London School of Hygiene and Tropical Medicine Masson, Lindi; Burnet Institute; University of Cape Town, IDDM Passmore, Jo-Anne; University of Cape Town, IDDM; Centre for the Aids Programme of Research in South Africa 'The Gift Study group, '; Institut Pasteur de Madagascar, Unit of Experimental Bacteriology; University of Cape Town, IDDM
<b>Primary Subject Heading</b>:	Diagnostics
Secondary Subject Heading:	Infectious diseases, HIV/AIDS
Keywords:	Sexually Transmitted Disease, BACTERIOLOGY, Public health < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

**A Novel Point-Of-Care Cytokine Biomarker Lateral Flow Test for the Screening for Sexually Transmitted Infections and Bacterial Vaginosis: Study Protocol of a Multi-Centre Multi-Disciplinary Prospective Observational Clinical Study to Evaluate the Performance and Feasibility of the Genital Inflammation Test (GIFT).**

Stéphanie Ramboarina<sup>1\*</sup>, Tania Crucitti<sup>1\*</sup>, Katherine Gill<sup>2</sup>, Linda-Gail Bekker<sup>2</sup>, Emma M Harding-Esch<sup>3</sup>, Janneke H H M van de Wijgert<sup>4</sup>, Bich-Tram Huynh<sup>5,6</sup>, Camille Fortas<sup>5,6</sup>, Aina Harimanana<sup>1</sup>, Théodora Mayouya Gamana<sup>1</sup>, Rindra Randremanana<sup>1</sup>, Reziky Mangahasimbola<sup>1</sup>, Chido Dziva Chikwari<sup>3,7,8</sup>, Katarina Kranzer<sup>3,9</sup>, Constance R S Mackworth-Young<sup>3</sup>, Sarah Bernays<sup>3,10</sup>, Nicola Thomas<sup>2</sup>, David Anderson<sup>11</sup>, Fatime-Ramla Tanko<sup>12,13,14,17</sup>, Monalisa Manhanzva<sup>12,14,17</sup>, Micaela Lurie<sup>12,14,17</sup>, Fezile Kumalo<sup>12,14,17</sup>, Edina Sinanovic<sup>15</sup>, Ayako Honda<sup>16</sup>, Tanya Pidwell<sup>12</sup>, Suzanna Francis<sup>3</sup>, Lindi Masson<sup>11,12,14,18,19</sup>, Jo-Ann Passmore<sup>12,14,17,19</sup> and the GIFT study group.

\*Equal contribution

§ Equal contribution

<sup>1</sup> Institut Pasteur de Madagascar, Madagascar

<sup>2</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa

<sup>3</sup> London School of Hygiene & Tropical Medicine, England

<sup>4</sup> Julius Center University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands

<sup>5</sup> Institut Pasteur, Université Paris Cité, France

<sup>6</sup> Université Paris-Saclay, Université Versailles Saint-Quentin, Inserm, France

<sup>7</sup> Organization for Public Health Interventions and Development, Zimbabwe

<sup>8</sup> The Biomedical Research and Training Institute, Zimbabwe

<sup>9</sup> Division of Infectious Diseases and Tropical

1  
2 Medicine, Medical Center of the University of Munich, Munich, Germany <sup>10</sup> School of Public  
3  
4 Health, University of Sydney, Australia

5  
6 <sup>11</sup> Disease Elimination Program, Life Sciences Discipline, Burnet Institute, Australia

7  
8  
9 <sup>12</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa

10  
11 <sup>13</sup> The Medical Research Centre, Institute of Medical Research and Medicinal Plant Studies (IMPM),  
12  
13 Ministry of Scientific Research and Innovation, Yaoundé, Cameroon

14  
15  
16 <sup>14</sup> Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South  
17  
18 Africa

19  
20  
21 <sup>15</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
22  
23 Town, South Africa

24  
25  
26 <sup>16</sup> Research Center for Health Policy and Economics, Hitotsubashi Institute for Advanced Study,  
27  
28 Hitotsubashi University, Japan

29  
30  
31 <sup>17</sup> Centre for the AIDS Programme of Research in South Africa, South Africa

32  
33  
34 <sup>18</sup> Central Clinical School, Monash University, Australia

35  
36  
37 <sup>19</sup> National Health Laboratory Service, Cape Town, South Africa

### 38 39 **GIFT study group**

40  
41 Eneyi Kpokiri<sup>1</sup>, Bahiah Meyer<sup>2</sup>, Phumla Radebe<sup>2</sup>, Conita Lombard<sup>2</sup>, Celia Mehrou-Loko<sup>2</sup>,  
42  
43 Yacoeb Ganief<sup>2</sup>, Rezeen Daniels<sup>3</sup>, Anda Madikida<sup>3</sup>, Karabo Mahlangu<sup>3</sup>, Tinashe Mwaturura<sup>4,5</sup>,  
44  
45 Mutsawashe Chisenga<sup>4,5</sup>, Joseph F Chipanga<sup>4,5</sup>, Tsitsi Bandason<sup>4,5</sup>, Patricia Makunyire<sup>4,5</sup>, Felicia  
46  
47 Mhangami<sup>4,5</sup>, Jayjay Karumazondo<sup>5</sup>, Jason Naidoo<sup>5</sup>, Karen Webb<sup>4</sup>, Lyndon Mungur<sup>6</sup>, Ashley Uys<sup>6</sup>,  
48  
49 Darryl Uys<sup>6</sup>, Elise Smith<sup>7</sup>, Saberi Marias<sup>8</sup>, Solange Rasoanandrianina<sup>9</sup>, Dimitri Ravoavison<sup>9</sup>, Patrick  
50  
51 Andry Rakotonirina<sup>9</sup>, Andrilaina Razakarivony<sup>9</sup>, Hantamalala Randria<sup>9</sup>, Alphonsine  
52  
53 Rahantarimalala<sup>9</sup>, Lala Rafetrarivony<sup>10</sup>, Barivola Bernardson<sup>10</sup>, Tsiry Rasolofomanana<sup>10</sup>, Norohasina  
54  
55 Randriamange<sup>10</sup>, Antsanirina Nomenjanahary<sup>10</sup>, Laura Rabarisoa<sup>10</sup>, Dimitri Rasoloson<sup>10</sup>, Sahara  
56  
57  
58  
59  
60

1  
2 Raveloson<sup>10</sup>, Laura Randrianantenaina<sup>10</sup>, Hanitratiavina Rakotonindriana<sup>10</sup>, Fenoso  
3  
4 Voanarivolalao<sup>10</sup>, Vaomalala Ranarinandra<sup>10</sup>, Farai Machinga<sup>11</sup>  
5  
6  
7

8  
9 <sup>1</sup> London School of Hygiene & Tropical Medicine, United Kingdom  
10

11 <sup>2</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa  
12

13 <sup>3</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa  
14

15 <sup>4</sup> Organization for Public Health Interventions and Development, Zimbabwe  
16

17 <sup>5</sup> The Biomedical Research and Training Institute, Zimbabwe  
18

19 <sup>6</sup> Medical Diagnostech, Cape Town, South Africa  
20

21 <sup>7</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
22  
23 Town, South Africa  
24

25 <sup>8</sup> Research Contracts and Innovation, University of Cape Town, South Africa  
26

27 <sup>9</sup> Centre Hospitalier Universitaire de Gynécologie et Obstétrique de Befelatanana, Antananarivo,  
28  
29 Madagascar  
30  
31

32 <sup>10</sup> Institut Pasteur de Madagascar, Madagascar  
33

34 <sup>11</sup> National Family Planning Council, Zimbabwe  
35  
36

37  
38 **Corresponding author:** Tania Crucitti, Experimental Bacteriology Unit, Institut Pasteur de  
39  
40 Madagascar, B.P. 1274. Ambatofotsikely - 101 Antananarivo, Madagascar. Tel : +261 20 22 412 72.  
41

42  
43 [tcrucitti@pasteur.mg](mailto:tcrucitti@pasteur.mg)  
44  
45

46  
47 **Word count: 6339**  
48

49  
50 **Keywords:** Sexually transmitted infections, bacterial vaginosis, lateral flow point of care test,  
51  
52 cytokines, genital inflammation test.  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

### Introduction

A prototype lateral flow device detecting cytokine biomarkers IL-1 $\alpha$  and IL-1 $\beta$  has been developed as a Point-of-Care (POC) test – called the Genital InFLammation Test (GIFT) - for detecting genital inflammation associated with sexually transmitted infections (STIs) and/or bacterial vaginosis (BV) in women. In this paper, we describe the rationale and design for studies that will be conducted in South Africa, Zimbabwe, and Madagascar to evaluate the performance of GIFT and how it could be integrated into routine care.

### Methods and analysis

We will conduct a prospective, multidisciplinary, multi-centre, cross-sectional, and observational clinical study comprising two distinct components: a biomedical (“diagnostic study”) and a qualitative, modelling, and economic (“an integration into care study”) part. The diagnostic study aims to evaluate GIFT’s performance in identifying asymptomatic women with discharge-causing STIs (*Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), *Trichomonas vaginalis* (TV) and *Mycoplasma genitalium* (MG)) and BV. Study participants will be recruited from women attending research sites and family planning services. Several vaginal swabs will be collected for the evaluation of cytokine concentrations (enzyme-linked immunosorbent assay), STIs (nucleic acid amplification tests), BV (Nugent Score), and vaginal microbiome characteristics (16S rRNA gene sequencing). The first collected vaginal swab will be used for the GIFT assay which will be performed in parallel by a healthcare worker in the clinic near the participant, and by a technician in the laboratory. The integration into care study aims to explore how GIFT could be integrated into routine care. Four activities will be conducted: user experiences and/or perceptions of the GIFT device involving qualitative focus group discussions and in-depth interviews with key stakeholders; discrete choice experiments; development of a decision tree classification algorithm; and economic evaluation of defined management algorithms.

### Ethics and dissemination

1  
2 Findings will be reported to participants, collaborators and local government for the three sites,  
3  
4 presented at national and international conferences, and disseminated in peer-reviewed publications.

5  
6 The protocol and all study documents such as informed consent forms were reviewed and approved  
7  
8 by the University of Cape Town Human Research Ethics Committee (HREC reference 366/2022),  
9  
10 Medical Research Council of Zimbabwe (MRCZ/A/2966), Comité d’Ethique pour la Recherche  
11  
12 Biomédicale de Madagascar (N° 143 MNSAP/SG/AMM/CERBM) and the London School of  
13  
14 Hygiene and Tropical Medicine ethics committee (LSHTM reference 28046).  
15  
16

17  
18 Before the start, this study was submitted to the Clinicaltrials.gov public registry (NCT05723484).  
19  
20  
21  
22

### 23 **Strengths and limitations of this study**

#### 24 **Strengths**

- 25 • A multicountry evaluation of a new low-cost, rapid POC test detecting vaginal inflammation to  
26 be conducted in three sub-Saharan countries characterised by different STI/BV contexts.
- 27 • Multidisciplinary approach, including social science, economic analysis, and machine learning to  
28 inform how the GIFT device could be integrated into STI management algorithms for women.

#### 29 **Limitations**

- 30 • The budget does not permit STI diagnosis using POC NAAT testing in Madagascar, in contrast  
31 to South Africa and Zimbabwe, leading to delays in delivering the diagnostic results and  
32 providing treatment to the Malagasy study participants.
- 33 • The user evaluation of the GIFT device does not include the evaluation nor quality assessment of  
34 the specimen extraction method.

## Introduction

Sexually transmitted infections (STIs) continue to pose a significant health challenge globally, with over one million new cases reported daily. In 2020, approximately 377 million new cases of the four most common STIs (*Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (NG), syphilis, and *Trichomonas vaginalis* (TV)) were documented, with over 70% occurring in low- and middle-income countries (LMICs), particularly in Sub-Saharan Africa and Latin America [1].

STIs impact women more than men, as women endure long-lasting consequences. Additionally, women are more susceptible to STIs than men due to anatomical and immunological differences [2,3]. The composition of the vaginal microbiome also plays a crucial role in sexual and reproductive health. Optimal vaginal microbiota, predominantly composed of *Lactobacillus* species, maintains an acidic pH, sustaining the vaginal epithelial barrier's integrity and preventing pathogen colonisation and invasion. However, various genetic, behavioural, and environmental factors can modulate this microbial composition and lead to bacterial vaginosis (BV) characterised by a decrease in protective *Lactobacillus* species along with an increase in bacterial diversity and vaginal pH [4-9].

BV remains a persistent public health issue, with prevalences ranging from 20-30% globally, and higher rates observed in Black populations compared to Caucasian or Asian populations [4, 6, 10]. In Sub-Saharan African populations, prevalences are notably high (around 33%) [10].

Both STIs and BV induce elevated genital inflammation, marked by increased local production of pro-inflammatory cytokines and chemokines, irrespective of symptoms [7, 11, 12, 13-15]. Studies in Sub-Saharan African women cohorts have shown that common STIs such as CT, NG, and TV significantly and consistently increased the concentrations of key genital tract cytokine biomarkers, including interleukin (IL)-1 $\alpha$  and  $\beta$  [14, 16, 17]. BV caused similar changes in these cytokine biomarkers, although was also shown to be associated with lower concentrations of the chemokine interferon- $\gamma$ -induced protein of 10kDa (IP-10) [12, 18, 19]. Genital inflammation caused by STIs and BV has in turn been associated with increased risk for the acquisition of other STIs, including HIV-

1 [20-25]. This is particularly concerning in Sub-Saharan African countries, where a significant proportion of new HIV-1 infections occur. The HIV-1 prevalence among adults (15-49 years) was estimated at 17.8% and 11% in South Africa and Zimbabwe, respectively in 2022. Women are disproportionately affected by HIV than men, with young women (15-24 years) particularly vulnerable with prevalence rates estimated at 8.7% and 4.4% in South Africa and Zimbabwe, respectively [26].

Both STIs and BV are also associated with other serious sexual and reproductive health complications, such as pelvic inflammatory disease which can lead to infertility and ectopic pregnancy and adversely affect a woman's reproductive plans. For prevalent bacterial STIs and BV, intrauterine infection and/or vertical transmission to the unborn child or during birth can result in adverse pregnancy and birth outcomes, including preterm delivery, maternal and neonatal sepsis, low birth weight, pneumonia, and conjunctivitis in the newborn [3, 27].

Despite the high prevalence of STIs and BV and their frequently asymptomatic nature, syndromic approaches remain the mainstay of management in LMICs [28]. Immediate testing and results delivery are crucial to facilitate prompt diagnosis and accurate treatment, reducing both STI transmission and infection progression [29-31]. Consequently, the inclusion of POC tests has been highly recommended for the management of symptomatic STIs [28]. Recently, nucleic acid amplification-based near-patient STI diagnostics have become available [32, 33], but none of them fulfils the REASSURED (including user-friendly, rapid, robust, equipment-free, and deliverable to end-users) criteria set out by World Health Organization (WHO) for POC tests [34].

Genital inflammation has been associated with a significantly increased risk of HIV acquisition in women and the presence of STIs driving this inflammation has been well described among South African women [11, 16, 22, 25]. To address the need for POC tests to improve STI/BV management for women in LMICs, Masson *et al.* have focused on developing a POC lateral flow test to detect a combination of inflammation biomarkers (IL-1 $\alpha$ , IL-1 $\beta$ , and IP-10), measured in lateral vaginal wall swabs, to improve BV and STI case finding in women compared to clinical signs [20]. This Genital

Inflammation Test (GIFT) screening tool aims to improve case detection to help identify women at increased risk of HIV infection and to enhance the sexual and reproductive health of women in countries where only syndromic management is available.

This study protocol outlines a study to be conducted in three countries (South Africa, Zimbabwe, and Madagascar) to evaluate the performance of the first-in-field GIFT prototype device and explore possible routes for integration into routine care.

### **Purpose and study objectives**

This multidisciplinary, cross-sectional, prospective, and multi-centric study has two distinctive sub-studies, a diagnostic evaluation and an integration into care study. Each sub-study has several objectives (Table 1).

**Table 1:** GIFT study objectives

	<b>Diagnostic study</b>	<b>Integration into care study</b>
<b>Primary objective</b>	To assess the sensitivity and specificity of the GIFT device at the point-of-care in South Africa, Zimbabwe, and Madagascar.	To evaluate how the GIFT device could be integrated into routine care

	Diagnostic study	Integration into care study
<b>Secondary objectives</b>	<ul style="list-style-type: none"> <li>To assess the predictive values of the GIFT device at the point-of-care</li> <li>To assess the performance of the GIFT device at the point-of-care</li> <li>To assess the performance of the device versus syndromic management without any laboratory testing (standard of care in South Africa, Zimbabwe, and Madagascar)</li> <li>To determine the robustness of the device by comparing results read by clinicians with those read by laboratory professionals, and with the results obtained using an automated reader</li> <li>To evaluate the accuracy of the GIFT device by comparing the GIFT device results with ELISA results using previously validated concentration cut-offs as the gold standard, including validation of the GIFT cytokine concentration cut-offs for each cytokine biomarker.</li> </ul>	<ul style="list-style-type: none"> <li>To qualitatively and quantitatively assess the user experience, usability, and acceptability of the GIFT device at the point of care;</li> <li>To examine patient preferences for various STI management aspects (attributes) to inform the development of STI management algorithms that integrate the GIFT device;</li> <li>To generate algorithms that integrate the GIFT device to optimise case finding and STIs/vaginal infection management in women, using the complete dataset from the study;</li> <li>To determine the cost and budget impact of the identified screening or diagnostic algorithm with the GIFT device, and to model the cost-effectiveness of different strategies of integration of GIFT into care.</li> </ul>
<b>Exploratory objectives</b>	<ul style="list-style-type: none"> <li>Determine if other determinants (such as intermediate microbiota (Nugent 4-6), age, parity, sexual activity) improve the prediction of STI/BV status in women</li> <li>To use 16S rRNA gene sequencing and vaginal bacteria specific quantitative NAATs to evaluate the proportion of cases of genital inflammation explained by vaginal dysbiosis that was not diagnosed as an STI or BV by NAATs or Nugent scoring</li> <li>To explore the performance of the device in the presence of vaginal <i>Candida</i> spp colonisation.</li> </ul>	

The diagnostic study aims to evaluate the performance of GIFT in identifying women with inflammatory STIs (including CT, NG, TV, and MG) and BV and who may, therefore, be at higher risk of STI and HIV infection and potential reproductive complications. Syndromic management in the absence of any diagnostic testing misses all asymptomatic reproductive tract infections by

1 definition, and GIFT may detect the presence of asymptomatic subclinical inflammation. Syndromic  
2 management guidelines currently call for women with cervicovaginal discharge to be treated for all  
3 reproductive tract infections that might cause such discharge, but studies have shown that a  
4 substantial proportion of these women do not have any infection [29]. In this scenario, GIFT may  
5 prevent overtreatment of symptomatic women without infection.  
6  
7  
8  
9  
10  
11  
12

13  
14 The primary objective is to assess the sensitivity and specificity of the GIFT device at the point-of-  
15 care in non-pregnant sexually active women aged 18-35 years accessing family planning services in  
16 South Africa, Zimbabwe, and Madagascar against nucleic acid amplification tests (NAATs) for CT,  
17 NG, TV, and MG plus BV by Nugent scoring (Table 1). Secondary objectives include assessing the  
18 device's predictive values; assessing performance in each country separately; assessing performance  
19 against syndromic management; assessing test reproducibility by comparing clinician- and  
20 laboratory-read results (visual reading versus automated reader); and setting the device's  
21 concentration cut-offs against gold standard cytokine concentrations (determined by enzyme-linked  
22 immunosorbent assay (ELISA)).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The integrative part of the study aims to explore the feasibility, acceptability, and cost-effectiveness  
37 of integrating GIFT into routine care in LMICs. The specific objectives include: assessing the user-  
38 experience, usability, and acceptability of the GIFT device at the POC; examining patient preferences  
39 for various STI management aspects to develop STI management algorithms; generation of  
40 algorithms that integrate the GIFT device to optimise case finding and STI/vaginal infection  
41 management in women; and determine the cost-effectiveness and budget impact of the identified  
42 algorithms with the GIFT device.  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **Methods and design**

### 53 *Study design*

54  
55  
56  
57  
58  
59  
60

1  
2 The diagnostic study will target women attending family planning services in each of the three study  
3 sites in South Africa, Zimbabwe, and Madagascar. A series of vaginal swabs will be collected by a  
4 midwife or nurse (Figure 1).  
5  
6  
7

8  
9 The first swab will be used to test the performance of the GIFT device. For each woman, the GIFT  
10 will be performed twice and read four times: one GIFT will be performed at the clinical site near the  
11 participant and visually read by a midwife or study nurse and a second GIFT will be done and visually  
12 read by a technician in the laboratory. The GIFT assays carried out by the midwife/study nurse and  
13 the laboratory technician will secondly be read using an automated lateral flow reader (Axxin,  
14 Fairfield, Australia) (Figure 1). The GIFT device performance in detecting (1) inflammation will be  
15 determined against cytokine enzyme-linked immunosorbent assay (ELISA); and (2) STIs/BV will be  
16 determined against the NAAT reference tests for CT, NG, TV, and MG and Nugent scoring for BV  
17 (Figure 1). All women will be offered treatment based on the on-site positive STI diagnostic results  
18 for CT, NG, and TV. Additionally, treatment for BV will be offered based on the Nugent score  
19 analysis and at the clinician's discretion.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 The integration into care study consists of four activities to determine how GIFT can be integrated in  
36 a feasible, acceptable, and cost-effective way into routine care and national guidelines in South  
37 Africa, Zimbabwe, and Madagascar (Figure 2): 1. User experiences and/or perceptions of the GIFT  
38 device involving qualitative focus group discussions (FGDs) and in-depth interviews (IDIs) with key  
39 stakeholders; 2. Discrete choice experiment (DCE); 3. Development of a decision tree classification  
40 algorithm; 4. Economic evaluation of defined management algorithms.  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 *Study sites*

51  
52  
53 The study will be performed in three countries: South Africa, Zimbabwe, and Madagascar. In contrast  
54 to South Africa and Zimbabwe which are countries bearing a high burden of STIs, including HIV,  
55 and BV [35-37], data on STI/BV prevalence are relatively scarce in Madagascar. BV, TV, and  
56 cervical infections (CT and NG) prevalences measured in a large population sample of symptomatic  
57  
58  
59  
60



1  
2 Malagasy women (N=1066) were high at 53%, 24%, and 17% respectively, suggesting a significant  
3  
4 burden of STIs/BV in the island [38]. Finally, Madagascar is less affected by HIV with a prevalence  
5  
6 <1% [39] compared to South Africa and Zimbabwe, which were found to have an HIV-1 prevalence  
7  
8 among adults (15-49 years) in 2022 of 17.8% and 11%, respectively [26].

9  
10  
11 In South Africa, the study will be conducted at the Desmond Tutu Health Foundation (DTHF)  
12  
13 Masiphumelele Youth Centre located in the South peninsula of Cape Town. The Masiphumelele  
14  
15 Research Site has been recognised as a pioneer in HIV prevention and adolescent research. The STI  
16  
17 and BV diagnostic testing of the South African participants will be performed in their on-site  
18  
19 laboratory. In addition, vaginal swabs collected at all three study sites will be tested for selected  
20  
21 cytokines including IL-1 $\alpha$ , IL-1 $\beta$ , and IP-10 by ELISAs and vaginal microbiome composition by 16S  
22  
23 rRNA gene sequencing being conducted at the University of Cape Town (UCT), along with samples  
24  
25 from the other two trial sites.  
26  
27  
28

29  
30 In Zimbabwe, the study will be conducted at the Spilhaus Family Planning Centre located in the  
31  
32 capital Harare. The study site is run by the Zimbabwe National Family Planning Council (ZNFPC)  
33  
34 in collaboration with the Zimbabwe Ministry of Health and Child Care. The study will be conducted  
35  
36 by researchers from the Organization for Public Health Interventions and Development (OPHID),  
37  
38 equipped with a skilled medical and technical team. The study site's laboratory will perform the STI  
39  
40 and BV diagnostic testing for Zimbabwean study participants.  
41  
42  
43

44  
45 In Madagascar, the study will be conducted at the Centre Hospitalier Universitaire de Gynécologie et  
46  
47 d'Obstétrique Gynéco-Obstétricaux de Befelatanana (CHU-GOB), a public university hospital that  
48  
49 specialises in obstetrics located in the capital of Madagascar, Antananarivo. Outpatient services  
50  
51 include prenatal consultations, family planning, obstetrics, and gynaecology services. Due to the lack  
52  
53 of recent data on STI/BV prevalences, a pre-study on CT, NG, TV, and MG prevalences was  
54  
55 conducted by the clinical and research team of IPM from March to December 2022 to confirm the  
56  
57 feasibility of conducting the GIFT study in the CHU-GOB in Antananarivo. The pre-study confirmed  
58  
59  
60

1  
2 the appropriateness of the clinical study site in terms of the study population's number and STI and  
3  
4 BV prevalence rates (results will be presented elsewhere).  
5  
6

7 The unit of experimental bacteriology (UBEX) at the Institut Pasteur Madagascar (IPM) will be the  
8  
9 study site's laboratory in Madagascar for diagnostic testing. UBEX is also designated as the reference  
10  
11 laboratory in the GIFT project for BV and STI (CT, NG, TV, and MG) comparator testing, as well as  
12  
13 quantification of lactobacilli and BV-associated bacteria using quantitative PCR and molecular  
14  
15 testing for the detection of *Candida* spp., and Y chromosome.  
16  
17

### 18 19 *Study participants and recruitment*

20  
21 The diagnostic study will enroll its participants from sexually active women aged 18-35 years  
22  
23 attending family planning services in each of the study's clinical sites, irrespective of symptoms.  
24  
25 Before study initiation, advice will be sought from local Community Advisory Boards (CABs) or  
26  
27 similar committees on the study material to be shared with potential study participants. The boards  
28  
29 will be regularly consulted regarding language to use for behavioural and other sensitive questions  
30  
31 included in the questionnaires. A CAB is currently not existing in Madagascar but will be installed  
32  
33 as part of the study.  
34  
35

36  
37 Due to the short recruitment period, sensitisation to the GIFT project will be extended in  
38  
39 Antananarivo (Madagascar) to the family planning services of surrounding primary health care  
40  
41 centres. In South Africa, the clinical study site offers family planning services to young women till  
42  
43 the age of 25, and women outside of the study site will be recruited to enroll women between 25 and  
44  
45 35 years old.  
46  
47

48  
49 Women interested in the diagnostic study will be invited to participate based on the inclusion and  
50  
51 exclusion criteria detailed in Table 2. Each woman will only be enrolled once.  
52  
53

54  
55  
56 **Table 2:** In- and exclusion criteria for both diagnostic and integration into care studies  
57  
58  
59  
60

	Diagnostic study	Integration into care study
<b>Inclusion criteria</b>	<ul style="list-style-type: none"> <li>• 18-35 years old</li> <li>• Willing and able to provide informed consent to participate in the study</li> <li>• Self-reported to be sexually active</li> <li>• Not pregnant (determined by pregnancy test)</li> <li>• Accessing family planning service</li> </ul>	<p>For all who are willing and able to provide informed consent to participate in the study.</p> <ul style="list-style-type: none"> <li>• User experiences/perceptions activity: <ul style="list-style-type: none"> <li>- Local or regional policymakers, programmers, and other opinion leaders and decision-makers</li> <li>- Healthcare professionals at health facilities</li> <li>- Women who are eligible for the diagnostic study (including pregnant and menstruating women), but who are not part of the diagnostic study</li> </ul> </li> <li>• Discrete choice experiments: Women who are eligible for the diagnostic study (including pregnant and menstruating women), who are either part of, or not part of, the diagnostic study</li> <li>• Decision tree classification algorithm: Data from diagnostic study participants</li> <li>• Economic evaluation: Healthcare professionals at health facilities involved in GIFT device implementation able to complete timesheets</li> </ul>
<b>Exclusion criteria</b>	<ul style="list-style-type: none"> <li>• &lt;18 years or &gt;35 years</li> <li>• Refusal by a participant to participate in the study</li> <li>• Treatment for any STI/BV in the past 30 days</li> <li>• Pregnancy</li> <li>• Enrolled in a study that does not allow co-enrolment in other studies</li> </ul>	<p>For all who are not willing or able to provide informed consent to participate in the study</p> <ul style="list-style-type: none"> <li>• User experiences/perceptions activity: <ul style="list-style-type: none"> <li>- Non-relevant policymakers</li> <li>- Healthcare professionals at health facilities not included in diagnostic study</li> </ul> </li> <li>- Women who are : <ul style="list-style-type: none"> <li>▸ part of the diagnostic study</li> <li>▸ &lt;18 years or &gt;35 years</li> <li>▸ Treated for any STI/BV in the past 30 days</li> <li>▸ Pregnant</li> <li>▸ Enrolled in a study that does not allow co-enrolment in other studies</li> </ul> </li> <li>• Decision tree classification algorithm: Participants for whom there are no diagnostic study data</li> <li>• Economic evaluation: Healthcare professionals not at study sites, not involved in GIFT device implementation, and/or not able to complete timesheets</li> </ul>

In addition to eligible women participating in the diagnostic study, participants for the integration into care study will include health care professionals (HCPs) including nurses, midwives, and matrons

1  
2 working at the clinical site where the diagnostic study is being conducted, women attending  
3  
4 gynaecological consultations at the study clinic, local and regional policymakers, programmers, other  
5  
6 opinion leaders, and decision-makers according to the inclusion and exclusion criteria (Table 2).  
7  
8

### 9 *Sample size*

10  
11 A total number of 675 women (225 women per site) will be enrolled for the diagnostic evaluation of  
12  
13 the prototype GIFT device. The sample size calculation is based on 7% precision, and an assumed  
14  
15 sensitivity of 77%, and a specificity of 71% of GIFT compared to NAATs for STIs and Nugent  
16  
17 scoring for BV [40].  
18  
19

20  
21  
22 No sample size calculations were performed for the qualitative research. A purposive sampling  
23  
24 strategy will be adopted to reflect maximum variation, as feasible, across the sample. It is anticipated  
25  
26 that the proposed number of participants per activity (FGDs and IDIs), per country, will enable  
27  
28 adequate data to be collected and saturation to be reached in the thematic analysis [41, 42]. Data  
29  
30 collection may be finalised before the planned sample size is reached, if saturation is reached first.  
31  
32

33  
34 For the DCE component of the study, using econometric criteria (including choice probability,  
35  
36 confidence level, accuracy level, attrition rate, and number of choice tasks), subgroups of more than  
37  
38 30 individuals are required to conduct meaningful statistical analysis [43, 44]. Because the DCE study  
39  
40 will undertake subgroup analysis on four to five groups (including respondent age group, socio-  
41  
42 economic status, location of residence, and experience with the GIFT device), up to 200 participants  
43  
44 per site will be recruited for the DCE study, with a quarter of the participants recruited on the  
45  
46 diagnostic study of the GIFT device, and reminder from women coming for gynecological  
47  
48 consultations at the study clinic.  
49  
50  
51

52  
53 No sample size calculation is needed for the decision tree algorithm study, which will use data from  
54  
55 the diagnostic study. Equally, there are no sample size requirements for the economic evaluation.  
56  
57  
58

### 59 *Study procedures and data collection*

#### 60 1) Diagnostic study

1  
2 The diagnostic study participant and sample flow from screening to laboratory results is described in  
3  
4 Figure 1 and detailed in Supplementary Figure 1 - Diagnostic study flow steps. After confirmation  
5  
6 that participants were eligible for the study (Table 2) and written informed consent obtained, enrolled  
7  
8 women will be interviewed using a structured questionnaire with questions including demographics,  
9  
10 sexual behaviour, hygiene habits, current medical and reproductive history, medication, and  
11  
12 symptoms. The data will be captured on paper or electronic case report forms (CRFs) (Figure 1). The  
13  
14 clinician, midwife, or study nurse will perform a physical examination including a pelvic  
15  
16 examination, and will collect finger prick blood for HIV testing and vaginal swabs using regular  
17  
18 flocked swabs (Copan, Italy) (Figure 1 and Supplementary Figure 1 - Diagnostic study flow steps).  
19  
20  
21

22  
23 The first inserted swab will be eluted in buffer and the nozzle-sample (provided with the GIFT kit)  
24  
25 will be applied to two prototype GIFT devices, one near the patient and the other in the laboratory  
26  
27 (Figure 1). A second swab will serve for cytokine ELISA testing, and a third swab for pH testing  
28  
29 using a pH indicator strip and to prepare a vaginal smear slide for BV (Figure 1). The next swabs will  
30  
31 be collected and used for CT, NG, and TV diagnosis in the laboratory, for reference STI testing  
32  
33 including MG, quantitative NAAT of vaginal microbiome bacteria, the detection of *Candida* spp, and  
34  
35 Y chromosome for the presence of semen. The last two collected swabs will be used to characterise  
36  
37 the vaginal microbiome by using 16S rRNA PCR and sequencing (Figure 1).  
38  
39  
40

## 41 42 2) Integration into care study

43  
44 The integration study is composed of four activities aiming to understand how GIFT can be integrated  
45  
46 into STI control (Figure 2).  
47

48  
49 For the qualitative study assessing the user-experience, usability, and acceptability of the GIFT device  
50  
51 at the point of care, data will be collected through IDIs and FGDs. Target groups will be: HCPs at the  
52  
53 health facilities; local or regional policymakers, programmers, other opinion leaders, and decision-  
54  
55 makers; and women who are eligible for the diagnostic study (Table 2), but who are not part of the  
56  
57 diagnostic study. HCP participants will be identified through the diagnostic study sites and will be  
58  
59 contacted directly to ask if they would be interested in participating. Policymakers recommended for  
60

1  
2 inclusion through snowball sampling will be contacted and asked if they would be interested in  
3  
4 participating. All women presenting at the family planning service facilities for inclusion in the  
5  
6 diagnostic study will be informed about the integration study. For the DCE, the study team will seek  
7  
8 to recruit women participating and not-participating in the GIFT diagnostic study to explore  
9  
10 heterogeneity in patient preferences for various STI attributes. For all population groups, those who  
11  
12 agree to participate will provide written informed consent, separate from the diagnostic study.  
13  
14

15  
16 For the decision tree classification algorithm, data will be obtained from the diagnostic study  
17  
18 participants, and no additional participants will be recruited. For the economic evaluation, healthcare  
19  
20 professionals at health facilities involved in GIFT device implementation and able to complete  
21  
22 timesheets will be recruited.  
23  
24

25  
26 For the user experience activity (Figure 2, activity 1), up to 10-12 IDIs and/or 1-3 FGDs will be  
27  
28 conducted with policy makers, up to 8-10 IDIs and/or 3 FGDs will be conducted with HCPs, and up  
29  
30 to 12-15 IDIs and/or 3 FGDs will be conducted with women. FGDs will include participatory tools,  
31  
32 such as card mapping. The FGDs with HCPs may additionally include role plays of how the providers  
33  
34 would discuss the GIFT device with women, and how providers would discuss GIFT device results  
35  
36 and subsequent care and management with women. IDIs will explore more detailed personal  
37  
38 perceptions of the potential structures of integration.  
39  
40  
41

42  
43 User experience data (qualitative and FGDs) on the patient experience will help inform the  
44  
45 development of attributes for the DCE (Figure 2, activity 2). The DCE aims to identify the relative  
46  
47 importance of factors influencing patients' preferences for the use of GIFT devices. For the DCE  
48  
49 study, face-to-face interviews using a questionnaire will be conducted, with the questionnaire asking  
50  
51 respondents to state preferences for hypothetical alternatives, each described by several attributes. A  
52  
53 D-efficient design will be used to identify the choice tasks to present to respondents. Each choice task  
54  
55 presents two STI screening test options that are defined using different levels of the attributes and  
56  
57 then ask respondents to choose their preferred option, with an opt-out option available (to choose  
58  
59 neither of the two options). The results of the DCE will inform the development of STI management  
60

1 algorithms that integrate the GIFT device, to increase the acceptability of the STI management  
2 programme.  
3  
4

5  
6  
7 A decision tree will be developed to classify symptomatic and asymptomatic women using the  
8 following attributes: socio-demographic information, signs and symptoms, medical history, sexual  
9 behaviour, the GIFT output, and vaginal pH. Different classifications will be tested by varying the  
10 combinations of the attributes and the number of levels of the tree. The algorithm will be developed  
11 using a training dataset (data from previous studies). After the development of the algorithm based  
12 on the training dataset, the algorithm will be tested on the data to be collected in the diagnostic study  
13 and refined if necessary. The algorithm will be designed to be as simple as possible (minimum number  
14 of nodes and minimum number of scenarios) and usable in routine practice. Finally, the management  
15 outcomes will be compared to those obtained with the WHO recommendations.  
16  
17  
18

19  
20  
21  
22  
23  
24  
25  
26  
27  
28 The economic evaluation (Figure 2, activity 4) will involve the collection of cost and service  
29 utilisation data from a provider's perspective at each of the clinical sites, using an ingredients-based  
30 approach. After obtaining approval from the facility and/or district, relevant facility management staff  
31 will be approached to share financial and other facility-level data. The cost and utilisation data will  
32 be collected from individual facility records and financial reports through cost data collection tools  
33 at each study site. The time that it takes to perform and analyse the GIFT assay will be obtained from  
34 clinical study staff. The time required for the delivery of routine family planning and STI services  
35 will be assessed through timesheets completed by selected healthcare workers at the study sites. These  
36 data will be captured in the Provider Cost Data Collection Tool by data collectors. This activity will  
37 determine the cost and budget impact of the identified screening or diagnostic algorithm with the  
38 GIFT device and will model the cost-effectiveness of the different strategies of integration of GIFT  
39 into care.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

55  
56  
57 *Laboratory procedures*  
58  
59  
60

1  
2 The BV diagnosis will be obtained from a vaginal smear carried out with the third swab collected  
3  
4 during the gynecological examination (Figure 1). The slide will be transferred from the clinic to the  
5  
6 respective on-site laboratory for Gram staining and Nugent scoring [40].  
7

8  
9 CT, NG, and TV diagnosis from collected vaginal swabs (Figure 1) will be performed using the  
10  
11 diagnostic tests available in each of the three sites. In South Africa and Zimbabwe, GeneXpert tests  
12  
13 (Cepheid, Sunnyvale, USA) will be used for CT and NG detection, and TV detection will be  
14  
15 performed with the OSOM trichomonas rapid test or TV GeneXpert test, depending on the  
16  
17 availability. In Madagascar, the vaginal swabs will be tested by UBEX (IPM) using validated qPCR  
18  
19 protocols for CT, NG, and TV detection [45,46].  
20  
21

22  
23 The swabs collected for STI reference testing in South Africa and Zimbabwe will be shipped to the  
24  
25 IPM (Madagascar) for reference testing using validated qPCR [45-47], vaginal bacteria-specific  
26  
27 quantitative qPCR testing, molecular detection of *Candida* spp. and presence of semen (Y  
28  
29 chromosome testing).  
30

31  
32 Three swabs per participant will be sent to the University of Cape Town, for cytokine ELISA  
33  
34 measurement and 16S rRNA gene PCR and sequencing. The results obtained with the prototype GIFT  
35  
36 device will be compared to the cytokine concentrations resulting from the ELISA measurements. 16S  
37  
38 rRNA gene sequencing and *Candida* spp. NAAT will be used to evaluate the proportion of cases of  
39  
40 genital inflammation that could be explained by vaginal bacterial or fungal dysbiosis, respectively.  
41  
42

43  
44 All testing will be performed blinded to the clinical information and results obtained at each of the  
45  
46 study sites, including the GIFT results.  
47

48  
49 The swabs will be stored in each study site at -80°C until shipment using dry ice to the respective  
50  
51 laboratories as stipulated above.  
52

### 53 54 55 *Monitoring, quality assurance, and control*

56  
57 This study will be monitored per regulations applicable to diagnostic study, including International  
58  
59 Committee on Harmonisation of Good Clinical Practice (ICH-GCP) and GCLP (Good Clinical  
60



1  
2 Laboratory Practices) requirements, and sponsor-specific standard operating procedures (SOP). The  
3  
4 diagnostic study will be monitored by the Epidemiology and Clinical Research Unit at the IPM.  
5  
6 Routine monitoring will be conducted throughout the study and at the study closure. All laboratory  
7  
8 activities including specimen transport, processing, testing, result reporting, and storage will be  
9  
10 conducted following clinical trial quality requirements. The GCLP guidelines will be followed and  
11  
12 the designated laboratories will perform testing according to the SOPs which will be documented in  
13  
14 the analytical plan.  
15  
16

17  
18 A batch of known negative and positive specimens for CT/NG, TV, pregnancy test, and slides for  
19  
20 Nugent scoring will be provided by the UBEX laboratory at IPM for external quality control. The  
21  
22 external quality control will consist of three panels to be tested at the start, middle, and end of the  
23  
24 study or every three months. Before the use of the GIFT devices, a lot validation will be performed  
25  
26 using the quality control panel provided by the manufacturer according to the SOP.  
27  
28

### 29 30 *Data management*

31  
32 The REDCap platform will be used as a clinical data management system (CDMS) for the clinical  
33  
34 study. Depending on the organisation in each study site data will be collected partially or fully using  
35  
36 paper CRF (pCRF) before being entered into REDCap daily. In addition, data may be collected and  
37  
38 entered in real-time into REDCap using tablets.  
39  
40

41  
42 The GIFT database will be managed by the Epidemiology and Clinical Research Unit at the IPM.  
43  
44 The quality and accuracy of CRF data transcription into the database will be verified weekly. Missing  
45  
46 or overdue forms will be identified and tracked using the REDCap field comment log. A control script  
47  
48 developed by the central data manager will check the double data entry, and any transcription  
49  
50 differences found will be noted. Status reporting including the list of inconsistencies will be done  
51  
52 weekly by the central data management team. The weekly reports will also resume the progress of  
53  
54 data collection and entry in each study site. All reports will be sent to the operational team for  
55  
56 verification and correction of the data, if required.  
57  
58  
59  
60

1  
2 External data sources not described on the CRF like cytokine ELISA data, the STI reference testing  
3 data, and 16S rRNA sequencing data will be reconciled against the CDMS at the end of the study.  
4  
5

6  
7 For the user experience study, FGD and IDI data will be audio-recorded and electronically transcribed  
8 into the national and/or local language of the study sites. The DCE questionnaire data will be captured  
9 electronically using REDcap and securely stored on a password-protected computer. Data for the  
10 economic evaluation will be collected in a Provider Cost: Data Collection Tool, and timesheets will  
11 be completed in Excel by HCPs.  
12  
13  
14  
15  
16  
17

## 18 19 **Data analysis**

### 20 21 *Diagnostic study*

22  
23 1) Primary analysis: Sensitivity and specificity estimated of the GIFT device with 95% confidence  
24 intervals using any positive etiological NAATs for STIs (CT, NG, TV and MG) or Nugent score  
25 result for BV as reference standards will be calculated. Visual readings of the GIFT device performed  
26 by the clinicians and technicians will be included separately in this analysis.  
27  
28

29  
30 2) Secondary analysis: Positive and negative predictive values with 95% confidence intervals of the  
31 GIFT device will be compared with the likelihood ratios using NAAT and Nugent scoring as  
32 reference standards overall and in each country (which may have different STI prevalence that will  
33 impact these predictive values).  
34  
35

36  
37 The performance of the GIFT device will be compared to the performance of syndromic management  
38 for detecting STIs. Both methods (GIFT and syndromic management) will be compared to any  
39 positive results of NAAT (for CT, NG, TV and MG) and/or BV detected by Nugent scoring.  
40 Agreement between the GIFT device results read visually by both the clinician and the laboratory  
41 technician and on an automated reader will be determined.  
42  
43

44  
45 The concordance of band intensity results from the GIFT device and cytokine ELISA measurements  
46 will be analysed. This analysis will be used to optimize the cytokine concentration cut-offs for  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 interpretation of the GIFT device performance, in terms of sensitivity, specificity, and predictive  
2 values.  
3  
4

5  
6 The impact of additional characteristics and/or determinants (such as intermediate microbiota,  
7 Candida, age, parity, and sexual activity) on the prediction of STI/BV status in women and the impact  
8 on the accuracy of the device will be determined.  
9  
10  
11  
12

### 13 *Integration into care study*

14  
15 For the user experience study, iterative thematic analysis will be applied to the IDI and FGD data,  
16 conducted by the qualitative research team. Sekhon's framework of acceptability of healthcare  
17 interventions will be used [48].  
18  
19  
20  
21  
22

23  
24 For the DCE, data will be analysed in STATA using the utility function modelled from two  
25 alternatives: a systematic (explainable) component and a random (unexplainable) component. To  
26 estimate the trade-offs that respondents are willing to make between attributes, willingness to pay  
27 (WTP) for marginal improvements in attributes will be estimated for all attributes. WTP estimates  
28 will be calculated as the ratio of the coefficient of interest to the negative of the coefficient on the  
29 attribute with continuous variables. Subgroup analyses will be undertaken to investigate how  
30 preferences are influenced by demographic characteristics, residential area, socio-economic status,  
31 and experience of point-of-care testing.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 The assessment of the decision tree classification algorithm will be based on the accuracy of the  
44 classification compared to the results of the gold standard methods (NAATs and Nugent score).  
45 Following this classification, different scenarios of management will be tested: immediate treatment,  
46 referral, re-evaluation, and no treatment. These scenarios will be optimised in order to avoid  
47 undertreatment and overtreatment by also considering immediate specific rapid diagnosis tests (if  
48 available) or risk scores for immediate presumptive treatment.  
49  
50  
51  
52  
53  
54  
55  
56

57 For the economic evaluation, models will be developed in Microsoft Excel. For the cost analysis, an  
58 ingredient-based model will be constructed, and for the budget impact analysis, an expenditure-based  
59  
60

1  
2 model will be applied. A decision-analysis model to estimate the cost and health outcomes associated  
3  
4 with different GIFT device implementation strategies will be developed. The main outcome will  
5  
6 measure the effectiveness of each approach in correctly diagnosing an STI and/or BV in women,  
7  
8 proxied by the sensitivity measure of the diagnostic test or approach, in comparison to the gold  
9  
10 standard NAATs and Nugent scoring. Secondary outcomes such as the performance of the device  
11  
12 versus syndromic management and the variation in device results when determined by a clinician,  
13  
14 laboratory technician or an automated reader, will be assessed by means of scenario analyses.  
15  
16 Univariate sensitivity analyses will be carried out to test the robustness of the findings.  
17  
18  
19  
20

### 21 **Ethics and dissemination**

22  
23 The study will be carried out according to the principles stated in the Declaration of Helsinki (as  
24  
25 amended in Seoul in 2008) and any further updates, all applicable national and international  
26  
27 regulations, and according to the most recent applicable principles of the GCP-ICH E6. All the  
28  
29 participants will be informed about the diagnostic results. The choice of treatment for STIs or BV  
30  
31 will be based on the current national guidelines in the three study sites.  
32  
33 The protocol and all study documents such as informed consent forms were reviewed and approved  
34  
35 by the University of Cape Town Human Research Ethics Committee (HREC reference 366/2022),  
36  
37 Medical Research Council of Zimbabwe (MRCZ/A/2966), Comité d'Ethique pour la Recherche  
38  
39 Biomédicale de Madagascar (N° 143 MNSAP/SG/AMM/CERBM) and the London School of  
40  
41 Hygiene and Tropical Medicine ethics committee (LSHTM reference 28046).  
42  
43  
44  
45  
46

47 Findings will be reported to participants, collaborators and local government for the three sites,  
48  
49 presented at national and international conferences and disseminated in peer-review publications.  
50  
51

52 Before the start, this study was submitted to the Clinicaltrials.gov public registry (NCT05723484).  
53  
54

### 55 **Patient and public involvement**

56  
57 Before study initiation, we will engage with established local community advisory boards (CAB) or  
58  
59 similar boards at each site. We will present the details of the study and ask for their input. According  
60

1 to the specific procedures in place in each site, we may allow the CAB to comment on the written  
2 protocol, the flyers, and the posters. We will also ask the CAB for their feedback on the language  
3 used in the flyers, posters, and informed consent forms. During the study, the study investigators will  
4 regularly attend CAB meetings to update on the progress of the study. We will also ensure that the  
5 CAB and the community are the first to receive the results of the study.  
6  
7  
8  
9  
10  
11  
12  
13

## 14 **Discussion**

15  
16  
17 Here, we have described the diagnostic and integration studies that will be used to validate the GIFT  
18 device as a proof-of-principle prototype for implementing a novel POC cytokine test to detect vaginal  
19 inflammation associated with STIs and/or BV among women in differing clinical settings.  
20  
21  
22  
23  
24

25 The development of low-cost rapid POC tests has become a major focus in the management of  
26 STIs/BV to replace or improve syndromic management widely adopted in Africa. The availability of  
27 these tests would offer all sexually active women the opportunity to be screened and treated. This  
28 may have particular benefit to women at high risk of STIs, including young women, pregnant women,  
29 female sex workers, and those with HIV.  
30  
31  
32  
33  
34  
35  
36

37 The results from the prospective diagnostic study will be closely combined with the results of the  
38 qualitative research, modeling, and economic evaluation. The feasibility and acceptability studies  
39 will inform how the GIFT device could be integrated into national guidelines. The GIFT feasibility  
40 study consists of a “user experience and GIFT perceptions” prototype involving a large spectrum of  
41 people selected from the general population (HCPs, sexually active women, policymakers) that will  
42 help extend STI/BV screening into family planning services in primary health care services at  
43 affordable costs for LMICs, with the aim that women should know about their health without delaying  
44 their treatment. The qualitative part of the study will improve our understanding of the different key  
45 factors contributing to the successful implementation of a novel screening device for STIs and BV in  
46 LMICs.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Besides evaluating a POC test for screening of STIs and BV, this study will be among the first of its  
3  
4 kind, focusing on STI/BV prevalence and risk factors including up to 675 women mainly from urban  
5  
6 areas in three sub-Saharan countries in different STI/BV contexts. The GIFT study will also improve  
7  
8 our knowledge in both biological and molecular characterisation of the three most common STIs (CT,  
9  
10 NG, and TV) and MG in association with the different states of the vaginal microbiota and will  
11  
12 provide new insights into the interplay between STI and BV.  
13  
14  
15

16  
17 Our study protocol has some limitations. First of all, the user evaluation of the GIFT device,  
18  
19 evaluating the performance of the device when applied by different types of users, does not include  
20  
21 the evaluation of the extraction step. The extraction step of the vaginal swab will be performed by  
22  
23 the medical staff only and not in parallel with a duplicate vaginal swab by a laboratory professional.  
24  
25 Secondly, due to budget constraints, the STI diagnostic testing in Madagascar will be conducted by  
26  
27 batch testing in the laboratory and not by POC NAAT testing as will be done in South Africa and  
28  
29 Zimbabwe. Consequently, Malagasy participants will receive their results and treatment, if needed,  
30  
31 after a delay of up to 10 days. This delay in treatment may facilitate further STI transmission.  
32  
33 However, the study clinician may decide on presumptive treatment in alignment with the routine care  
34  
35 practice in place.  
36  
37  
38  
39

40  
41 In conclusion, the multidisciplinary study will be instrumental in developing strategies to improve  
42  
43 STI and BV management in LMICs.  
44  
45

#### 46 **Study status**

47  
48 The study is ongoing. Data collection and data analysis are ongoing.  
49  
50  
51  
52  
53  
54  
55  
56  
57

#### 58 **DECLARATIONS**

#### 59 **Consent for publication**

60

1  
2 Not applicable  
3

#### 4 **Availability of data and materials**

5

6 Not applicable. The study is ongoing. Data collection and data analysis are ongoing.  
7

#### 8 **Competing interests**

9

10 The last authors, Jo-Ann Passmore and Lindi Masson, declare sharing a patent for the biomarkers for  
11 GIFT: patent number PCT/IB 2014/065740, October 2014. All other authors declared no potential  
12 conflict of interest.  
13  
14  
15  
16

#### 17 **Funding**

18

19 The study is funded by the EDCTP through the EDCTP2 programme supported by the European  
20 Union (grant number EDCTP-RIA2020I-3297-GIFT). The views and opinions of authors expressed  
21 herein do not necessarily state or reflect those of EDCTP.  
22  
23  
24  
25  
26

#### 27 **Author Contributions**

28

29 Stéphanie Ramboarina and Tania Crucitti wrote the first draft of the manuscript. Lindi Masson  
30 designed Figure 1, Emma M Harding-Esch and Stéphanie Ramboarina designed Figure 2. All authors  
31 contributed to the writing, and reviewed and approved the manuscript. Stéphanie Ramboarina  
32 reformatted the manuscript. Lindi Masson and Jo-Ann Passmore validated the final version. All  
33 authors were involved in the conception of the study and contributed to the design of the study  
34 protocol. Tania Crucitti led the design of the diagnostic study with the participation of Katherine Gill  
35 Linda-Gail Bekker, Janneke H H M van de Wijgert, Aina Harimanana, Théodora Mayouya Gamana,  
36 Rindra Randremanana, Reziky Mangahasimbola, Chido Dziva Chikwar, Katarina Kranzer, Nicola  
37 Thomas, David Anderson, Fatime-Ramla Tanko, Monalisa Manhanzva, Micaela Lurie, Fezile  
38 Kumalo, Lindi Masson, Jo-Ann Passmore. Emma M Harding-Esch led the design of the integration  
39 into care study with the participation of Bich-Tram Huynh, Camille Fortas, Constance R S  
40 Mackworth-Young, Sarah Bernays, Edina Sinanovic, Ayako Honda, Suzanna Francis, Lindi Masson,  
41 Jo-Ann Passmore. The protocol development was facilitated by Tanya Pidwell; and validated by  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Lindi Masson, Jo-Ann Passmore principal investigators of the study. All authors and all members of the study group contribute to the diagnostic and integration study.

## References

1. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Broutet N, Taylor MM. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. *Bull World Health Organ.* 2019 Aug 1;97(8):548-562P. doi: 10.2471/BLT.18.228486.
2. Tuddenham S, Ravel J, Marrazzo JM. Protection and Risk: Male and Female Genital Microbiota and Sexually Transmitted Infections. *J Infect Dis.* 2021;223 (12 Suppl 2):S222-S235. doi: 10.1093/infdis/jiaa762.
3. Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. *Nat Microbiol.* 2022;7(8):1116-1126. doi: 10.1038/s41564-022-01177-x.
4. Ness RB, Hillier S, Richter HE, Soper DE, Stamm C, Bass DC, Sweet RL, Rice P. Can known risk factors explain racial differences in the occurrence of bacterial vaginosis? *J Natl Med Assoc.* 2003;95(3):201-12.
5. Yotebieng M, Turner AN, Hoke TH, Van Damme K, Rasolofomanana JR, Behets F. Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status. *Trop Med Int Health.* 2009;14(4):480-6. doi: 10.1111/j.1365-3156.2009.02235.x.
6. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. *Am J Obstet Gynecol.* 2013;209:505–23.
7. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung'u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. Cervicovaginal bacteria are a major



- 1  
2 modulator of host inflammatory responses in the female genital tract. *Immunity*. 2015;42(5):965-76.  
3  
4 doi: 10.1016/j.immuni.2015.04.019.  
5  
6 8. Jespers V, van de Wijgert J, Cools P, Verhelst R, Verstraelen H, Delany-Moretlwe S, Mwaura M,  
7  
8 Ndayisaba GF, Mandaliya K, Menten J, Hardy L, Crucitti T; Vaginal Biomarkers Study Group. The  
9  
10 significance of *Lactobacillus crispatus* and *L. vaginalis* for vaginal health and the negative effect of  
11  
12 recent sex: a cross-sectional descriptive study across groups of African women. *BMC Infect Dis*.  
13  
14 2015;15:115. doi: 10.1186/s12879-015-0825-z.  
15  
16  
17 9. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ. Understanding vaginal microbiome  
18  
19 complexity from an ecological perspective. *Transl Res*. 2012;160(4):267-82. doi:  
20  
21 10.1016/j.trsl.2012.02.008.  
22  
23  
24 10. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High Global Burden and Costs  
25  
26 of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. *Sex Transm Dis*. 2019;46(5):304-  
27  
28 311. doi: 10.1097/OLQ.0000000000000972.  
29  
30  
31 11. Adapen C, Réot L, Menu E. Role of the human vaginal microbiota in the regulation of  
32  
33 inflammation and sexually transmitted infection acquisition: Contribution of the non-human primate  
34  
35 model to a better understanding? *Front Reprod Health*. 2022;4:992176. doi:  
36  
37 10.3389/frph.2022.992176.  
38  
39  
40 12. Kyongo JK, Crucitti T, Menten J, Hardy L, Cools P, Michiels J, Delany-Moretlwe S, Mwaura M,  
41  
42 Ndayisaba G, Joseph S, Fichorova R, van de Wijgert J, Vanham G, Ariën KK, Jespers V. Cross-  
43  
44 Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal  
45  
46 Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention. *Clin*  
47  
48 *Vaccine Immunol*. 2015;22(5):526-38. doi: 10.1128/CVI.00762-14.  
49  
50  
51 13. Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the Vaginal Microbiome Alter  
52  
53 the Innate Immune Response and Barrier Properties of the Human Vaginal Epithelia in a Species-  
54  
55 Specific Manner. *J Infect Dis*. 2014;209 (12):1989–99. doi: 10.1093/infdis/jiu004  
56  
57  
58  
59  
60

- 1  
2 14. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, Gamieldien H, Williamson  
3  
4 C, Mckinnon LR, Walzl G, Karim QA. Defining genital tract cytokine signatures of sexually  
5  
6 transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-  
7  
8 sectional study. *Sex Transm Infect.* 2014;90(8):580-7.  
9  
10  
11 15. Mtshali A, Ngcapu S, Mindel A, Garrett N, Liebenberg L. HIV susceptibility in women: The roles  
12  
13 of genital inflammation, sexually transmitted infections and the genital microbiome. *J Reprod*  
14  
15 *Immunol.* 2021;145:103291. doi: 10.1016/j.jri.2021.103291.  
16  
17  
18 16. Masson L, Arnold KB, Little F, Mlisana K, Lewis DA, Mkhize N, Gamieldien H, Ngcapu S,  
19  
20 Johnson L, Lauffenburger DA, Abdool Karim Q, Abdool Karim SS, Passmore JA. Inflammatory  
21  
22 cytokine biomarkers to identify women with asymptomatic sexually transmitted infections and  
23  
24 bacterial vaginosis who are at high risk of HIV infection. *Sex Transm Infect.* 2016;92(3):186-93.  
25  
26  
27 17. Filardo S, Di Pietro M, Tranquilli G, Latino MA, Recine N, Porpora MG, Sessa R. 2019. Selected  
28  
29 immunological mediators and cervical microbial signatures in women with *Chlamydia trachomatis*  
30  
31 infection. *mSystems* 4:e00094-19. <https://doi.org/10.1128/mSystems.00094-19>.  
32  
33  
34 18. Jaspers V, Kyongo J, Joseph S, Hardy L, Cools P, Crucitti T, Mwaura M, Ndayisaba G, Delany-  
35  
36 Moretlwe S, Buyze J, Vanham G. A longitudinal analysis of the vaginal microbiota and vaginal  
37  
38 immune mediators in women from sub-Saharan Africa. *Sci. Rep.* 2017;7(1):1-3.  
39  
40  
41 19. Masson L, Barnabas S, Deese J, Lennard K, Dabee S, Gamieldien H, Jaumdally SZ, Williamson  
42  
43 AL, Little F, Van Damme L, Ahmed K. Inflammatory cytokine biomarkers of asymptomatic sexually  
44  
45 transmitted infections and vaginal dysbiosis: a multicentre validation study. *Sex Transm Infect.*  
46  
47 2019;95(1):5-12.  
48  
49  
50 20. Galvin SR and Cohen MS. The role of sexually transmitted diseases in HIV transmission. *Nat*  
51  
52 *Rev Microbiol.* 2004;2(1):33-42. doi: 10.1038/nrmicro794.  
53  
54  
55 21. Borgdorff H, Tsvitshivadze E, Verhelst R, Marzorati M, Jurriaans S, Ndayisaba GF, Schuren FH,  
56  
57 van de Wijgert JH. Lactobacillus-dominated cervicovaginal microbiota associated with reduced  
58  
59  
60

- 1  
2 HIV/STI prevalence and genital HIV viral load in African women. *ISME J.* 2014;8(9):1781-93. doi:  
3  
4 10.1038/ismej.2014.26.  
5  
6 22. Masson L, Passmore JA, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little  
7  
8 F, Mansoor LE, Naranbhai V, Lauffenburger DA. Genital inflammation and the risk of HIV  
9  
10 acquisition in women. *Clin. Infect. Dis.* 2015;61(2):260-9.  
11  
12  
13 23. McClelland RS, Lingappa JR, Srinivasan S, Kinuthia J, John-Stewart GC, Jaoko W, et al.  
14  
15 Evaluation of the association between the concentrations of key vaginal bacteria and the increased  
16  
17 risk of HIV acquisition in african women from five cohorts: a nested case-control study. *Lancet Infect*  
18  
19 *Dis.* 2018;18:554–64. doi: 10.1016/S1473-3099(18)30058-6  
20  
21  
22 24. Jarrett OD, Srinivasan S, Richardson BA, Fiedler T, Wallis JM, Kinuthia J, et al. Specific vaginal  
23  
24 bacteria are associated with an increased risk of trichomonas vaginalis acquisition in women. *J Infect*  
25  
26 *Dis.* 2019;220:1503–10. doi: 10.1093/infdis/jiz354.  
27  
28  
29 25. McKinnon LR, Achilles SL, Bradshaw CS, et al. The evolving facets of bacterial vaginosis:  
30  
31 implications for HIV transmission. *AIDS Res Hum Retroviruses* **2019**; 35:219–28.  
32  
33  
34 26. GBD 2015 HIV collaboarators, *Lancet HIV* 2016; 3: e361–87. [http://dx.doi.org/10.1016/S2352-](http://dx.doi.org/10.1016/S2352-3018(16)30087-X)  
35  
36 [3018\(16\)30087-X](http://dx.doi.org/10.1016/S2352-3018(16)30087-X).  
37  
38  
39 27. Fettweis JM, Serrano MG, Brooks JP, Edwards DJ, Girerd PH, Parikh HI, et al. The Vaginal  
40  
41 Microbiome and Preterm Birth. *Nat Med.* 2019;25(6):1012–21. doi: 10.1038/s41591-019-0450-2.  
42  
43  
44 28. Guidelines for the management of symptomatic sexually transmitted infections. Geneva: World  
45  
46 Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.  
47  
48 29. Verwijs MC, Agaba SK, Sumanyi JC, Umulisa MM, Mwambarangwe L, Musengamana V,  
49  
50 Uwineza M, Cuylaerts V, Crucitti T, Jespers V, Van De Wijgert JH. Targeted point-of-care testing  
51  
52 compared with syndromic management of urogenital infections in women (WISH): a cross-sectional  
53  
54 screening and diagnostic accuracy study. *Lancet Infect Dis.* 2019;19(6):658-69.  
55  
56  
57 30. Garrett N, Mtshali A, Osman F, Masson L, McKinnon LR, Singh R, Mitchev N, Ngobese H,  
58  
59 Kharsany ABM, Abdool Karim S, Mlisana K, Passmore JA, Rompalo A, Mindel A, Liebenberg L.

- 1  
2 Impact of point-of-care testing and treatment of sexually transmitted infections and bacterial  
3  
4 vaginosis on genital tract inflammatory cytokines in a cohort of young South African women. *Sex*  
5  
6 *Transm Infect.* 2021;97(8):555-565. doi: 10.1136/sextrans-2020-054740.  
7  
8  
9 31. Asare K, Andine T, Naicker N, Dorward J, Singh N, Spooner E, Andriesen J, Osman F, Ngcapu  
10  
11 S, Vandormael A, Mindel A, Abdool Karim SS, Bekker LG, Gray G, Corey L, Tomita A, Garrett N.  
12  
13 Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South  
14  
15 Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial. *Clin Infect*  
16  
17 *Dis.* 2023;76(5):881-889. doi: 10.1093/cid/ciac824. Erratum in: *Clin Infect Dis.* 2023;76(1):182.  
18  
19  
20 32. Adamson PC, Loeffelholz MJ, Klausner JD. Point-of-Care Testing for Sexually Transmitted  
21  
22 Infections: A Review of Recent Developments. *Arch Pathol Lab Med.* 2020;144(11):1344-1351.  
23  
24  
25 33. The diagnostics landscape for sexually transmitted infections. Geneva: World Health  
26  
27 Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.  
28  
29  
30 34. Land, K.J., Boeras, D.I., Chen, X.S. *et al.* REASSURED diagnostics to inform disease control  
31  
32 strategies, strengthen health systems and improve patient outcomes. *Nat Microbiol* 4, 46–54 (2019).  
33  
34 <https://doi.org/10.1038/s41564-018-0295-3>  
35  
36  
37 35. Torrone EA, Morrison CS, Chen P-L, Kwok C, Francis SC, Hayes RJ, et al. (2018) Prevalence  
38  
39 of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An  
40  
41 individual participant data meta-analysis of 18 HIV prevention studies. *PLoS Med.* 2018;15(2):  
42  
43 e1002511.  
44  
45  
46 36. Wand H, Reddy T, Dassaye R, Moodley J, Naidoo S, Ramjee G. Estimating prevalence and  
47  
48 incidence of sexually transmitted infections among South African women: Implications of combined  
49  
50 impacts of risk factors. *Int J STD AIDS.* 2020;31(11):1093-1101. doi: 10.1177/0956462420915388.  
51  
52  
53 37. Delany-Moretlwe S, Mgodhi N, Bekker L, et al. High prevalence and incidence of gonorrhoea and  
54  
55 chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and  
56  
57 Zimbabwe: results from the HPTN 082 trial. *Sex Transm Infect.* 2023;99:433-439.  
58  
59  
60

- 1  
2 38. Behets F, Andriamiadana J, Rasamilalao D, Ratsimbazafy N, Randrianasolo D, Dallabetta G,  
3  
4 Cohen M. Sexually transmitted infections and associated socio-demographic and behavioural factors  
5  
6 in women seeking primary care suggest Madagascar's vulnerability to rapid HIV spread. *Trop Med*  
7  
8 *Int Health*. 2001;6(3):202-11.
- 9  
10 39. Country factsheets, UNAIDS 2023.  
11  
12 <https://www.unaids.org/en/regionscountries/countries/madagascar>.  
13  
14
- 15 40. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis improved by a  
16  
17 standardized method of gram stain interpretation. *J Clin Microbiol*. 1991;29:297e301.
- 18  
19 41. Dworkin, S.L. specimen Size Policy for Qualitative Studies Using In-Depth Interviews. *Arch Sex*  
20  
21 *Behav* 2012; 41, 1319–1320.
- 22  
23 42. Guest G, Namey E, McKenna K. How Many Focus Groups Are Enough? Building an Evidence  
24  
25 Base for Nonprobability specimen Sizes. *Field Methods*. 2017;29(1):3-22.
- 26  
27 43. Louviere J, Hensher D, Swait J: *Stated Choice Methods: Analysis and Application*, First edition  
28  
29 edn. Cambridge, United Kingdom: Cambridge University Press; 2000.
- 30  
31 44 Ryan M, Gerard K, Amaya-Amaya M (eds.): *Using Discrete Choice Experiments to Value Health*  
32  
33 *and Health Care*. Dordrecht, the Netherlands: Springer; 2008.
- 34  
35 45. PRESTO CT/NG combined qualitative real time CT/NG assay (Kit # GM CG 160500). Goffin  
36  
37 Molecular Technologies, the Netherlands
- 38  
39 46. Crucitti T, Van Dyck E, Tehe A, Abdellati S, Vuylsteke B, Buve A, Laga M. Comparison of  
40  
41 culture and different PCR assays for detection of *Trichomonas vaginalis* in self collected vaginal  
42  
43 swab specimens. *Sex Transm Infect*. 2003 Oct;79(5):393-8. doi: 10.1136/sti.79.5.393. PMID:  
44  
45 14573835; PMCID: PMC1744760.
- 46  
47 47. Müller EE, Venter JM, Magooa MP, Morrison C, Lewis DA, Mavedzenge SN. Development of  
48  
49 a rotor-gene real-time PCR assay for the detection and quantification of *Mycoplasma genitalium*. *J*  
50  
51 *Microbiol Methods*. 2012 Feb;88(2):311-5. doi: 10.1016/j.mimet.2011.12.017. Epub 2011 Dec 29.  
52  
53 PMID: 22230235.
- 54  
55  
56  
57  
58  
59  
60

1  
2 48. Sekhon, M., Cartwright, M. & Francis, J.J. Acceptability of healthcare interventions: an overview  
3  
4 of reviews and development of a theoretical framework. BMC Health Serv Res. 2017;17, 88.  
5  
6 <https://doi.org/10.1186/s12913-017-2031-8>.  
7  
8  
9

## 10 11 **Acknowledgements**

12  
13 We thank in advance all women who will participate in this study and the healthcare workers who  
14  
15 will be involved in the recruitment and enrolment of the study participants.

16  
17 We would also like to thank EDCTP and the members of GIFT study group for making this study  
18  
19 possible. We thank the members of the community advisory boards for their valuable advice.

20  
21 We are extremely grateful to the members of the scientific advisory board for the precious scientific  
22  
23 discussions and suggestions for improving our study.  
24  
25

## 26 27 **GIFT study group**

28  
29 Eneyi Kpokiri<sup>1</sup>, Bahiah Meyer<sup>2</sup>, Phumla Radebe<sup>2</sup>, Conita Lombard<sup>2</sup>, Celia Mehrou-Loko<sup>2</sup>,  
30  
31 Yacoeb Ganief<sup>2</sup>, Rezeen Daniels<sup>3</sup>, Anda Madikida<sup>3</sup>, Karabo Mahlangu<sup>3</sup>, Tinashe Mwaturura<sup>4,5</sup>,  
32  
33 Mutsawashe Chisenga<sup>4,5</sup>, Joseph F Chipanga<sup>4,5</sup>, Tsitsi Bandason<sup>4,5</sup>, Patricia Makunyire<sup>4,5</sup>, Felicia  
34  
35 Mhangami<sup>4,5</sup>, Jayjay Karumazondo<sup>5</sup>, Jason Naidoo<sup>5</sup>, Karen Webb<sup>4</sup>, Lyndon Mungur<sup>6</sup>, Ashley Uys<sup>6</sup>,  
36  
37 Darryl Uys<sup>6</sup>, Elise Smith<sup>7</sup>, Saberi Marias<sup>8</sup>, Solange Rasoanandrianina<sup>9</sup>, Dimitri Ravoavison<sup>9</sup>, Patrick  
38  
39 Andry Rakotonirina<sup>9</sup>, Andrilaina Razakarivony<sup>9</sup>, Hantamalala Randria<sup>9</sup>, Alphonsine  
40  
41 Rahantarimalala<sup>9</sup>, Lala Rafetrarivony<sup>10</sup>, Barivola Bernardson<sup>10</sup>, Tsiry Rasolofomanana<sup>10</sup>, Norohasina  
42  
43 Randriamange<sup>10</sup>, Antsanirina Nomenjanahary<sup>10</sup>, Laurah Rabarisoa<sup>10</sup>, Dimitri Rasoloson<sup>10</sup>, Sahara  
44  
45 Raveloson<sup>10</sup>, Laura Randrianantenaina<sup>10</sup>, Hanitratiavina Rakotonindriana<sup>10</sup>, Fenosoa  
46  
47 Voanarivolalao<sup>10</sup>, Vaomalala Ranarinandra<sup>10</sup>, Farai Machinga<sup>11</sup>  
48  
49  
50  
51  
52  
53  
54

55 <sup>1</sup> London School of Hygiene & Tropical Medicine, United Kingdom

56  
57 <sup>2</sup> Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa

58  
59 <sup>3</sup> Desmond Tutu HIV Centre, University of Cape Town, South Africa  
60

1  
2 <sup>4</sup> Organization for Public Health Interventions and Development, Zimbabwe

3  
4 <sup>5</sup> The Biomedical Research and Training Institute, Zimbabwe

5  
6 <sup>6</sup> Medical Diagnostech, Cape Town, South Africa

7  
8  
9 <sup>7</sup> Health Economics Unit, School of Public Health, Faculty of Health Sciences, University of Cape  
10  
11 Town, South Africa

12  
13 <sup>8</sup> Research Contracts and Innovation, University of Cape Town, South Africa

14  
15  
16 <sup>9</sup> Centre Hospitalier Universitaire de Gynécologie et Obstétrique de Befelatanana, Antananarivo,  
17  
18 Madagascar

19  
20 <sup>10</sup> Institut Pasteur de Madagascar, Madagascar

21  
22  
23 <sup>11</sup> National Family Planning Council, Zimbabwe

## 24 25 26 27 **Figure Legend**

### 28 29 **Figure 1: Schematic of the GIFT diagnostic study**

30  
31  
32 The recruited women who meet the inclusion criteria and consent to participate in the GIFT study  
33  
34 will be administered a questionnaire. Data will be recorded on case report forms (CRF) in a paper or  
35  
36 electronic (tablet) format by the clinical nurse followed by a gynecological exam. Vaginal swabs are  
37  
38 collected: the first collected swab will be used for two GIFT assays: the first GIFT will be performed  
39  
40 at the bedside by the midwife/nurse and the second GIFT by the lab technician. Each of them will  
41  
42 read visually their own performed GIFT (naked eye reading). The two respective GIFT assays will  
43  
44 then be read using a lateral flow automated reader. The other collected swabs will be used for different  
45  
46 laboratory assays for the evaluation of the GIFT performance. HIV testing on fingerpick blood will  
47  
48 be also included at the end of the medical exam. The figure was created with BioRender.

### 49 50 51 52 53 54 **Figure 2: Integration study activities**

55  
56  
57 Description of the four activities that will be performed for the GIFT integration into care study for  
58  
59 improving the STI/BV diagnosis and control in women: 1) user experiences and/or perceptions of the  
60


1  
2 GIFT device involving qualitative focus group discussions and in-depth interviews with key  
3 stakeholders, 2) discrete choice experiments, 3) development of a decision tree classification  
4 algorithm and 4) economic evaluation of defined management algorithms. In addition to the women  
5 already participating to the GIFT diagnostic study, health care professionals (HCP), policy makers,  
6 key opinion leaders and patients coming for consultation will be included in the study.  
7  
8  
9  
10  
11  
12

### 13 14 **Additional files**

#### 15 16 **Supplementary figure 1 : Diagnostic study flow steps**

17  
18 Description: Women attending family planning services will receive explanations on the GIFT study.  
19  
20 After written consent and validation of the eligibility criteria and written informed consent, the  
21 enrolled woman will be subjected to a structured questionnaire. The data will be captured on paper  
22 or electronic case report form (CRF) by the clinical nurse. The CRF consists of 8 modules that will  
23 include all the information from sociodemographic information, behavioral risk assessment to  
24 medical information collected during the gynecological examination by the midwife or nurse.  
25  
26 Each CRF assigned to each participant will contain all the data collected through the diagnostic study  
27 including laboratory results that will be recorded in the REDCap GIFT database.  
28  
29 The vaginal swab sample collection will be done by the midwife/nurse after gynecological  
30 examination for : GIFT assays, pH measurement and microscopic analysis of a vaginal smear slide  
31 for BV diagnosis, and STI diagnosis. For this latter, a couple of vaginal swabs will be used for nucleic-  
32 acid amplification tests (NAAT) for CT, NG and TV to be performed locally on each study site.  
33  
34 Based on the on-site positive diagnostic results for CT, NG, TV and BV a treatment will be offered  
35 by the clinic or hospital clinician to the participant. HIV will be tested on fingerprick blood.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





The recruited women who meet the inclusion criteria and consent to participate in the GIFT study will be administered a questionnaire. Data will be recorded on case report forms (CRF) in a paper or electronic (tablet) format by the clinical nurse followed by a gynecological exam. Vaginal swabs are collected: the first collected swab will be used for two GIFT assays: the first GIFT will be performed at the bedside by the midwife/nurse and the second GIFT by the lab technician. Each of them will read visually their own performed GIFT (naked eye reading). The two respective GIFT assays will then be read using a lateral flow automated reader. The other collected swabs will be used for different laboratory assays for the evaluation of the GIFT performance. HIV testing on fingerpick blood will be also included at the end of the medical exam. The figure was created with BioRender.

645x452mm (118 x 118 DPI)

## USER EXPERIENCES AND GIFT PERCEPTIONS

- **Research questions**
  - how HCPs would use the GIFT device?
  - where the GIFT device would be placed within a health facility
  - how it would fit into the clinic flow?
  - What are the setting-specific barriers to and facilitators of using the GIFT device for the patient?
  - What counseling advice would be needed when using the GIFT device?
- **Target groups**
  - Health care professionals
  - Policy makers
  - Key opinion leaders
  - Patients

## DISCRETE CHOICE EXPERIMENTS (DCE)

- **Research questions**
  - What are the user (patient) preferences for a patient management algorithm?
  - What is the preference heterogeneity across users?
  - Willingness to pay?
- **Target groups**
  - Women participant to the diagnostic study
  - Women non included in the diagnostic study

## DECISION TREE

- **Research questions**
  - What is the risk profile of women who test positive on the GIFT test?
  - How do different testing strategies (immediate treatment after GIFT positive vs further re-evaluation) affect outcomes?
  - If immediate treatment, which treatment would yield the best outcome?

## ECONOMIC EVALUATION

- **Research questions**
  - What are the costs and budget impact of the identified screening or diagnostic algorithm with the GIFT device?
  - What are the costs of the different algorithms and strategies for GIFT device integration?

**INTEGRATION OF GIFT  
INTO STI/BV CONTROL**

**SCREENING**

Explanation about the study to women attending family planning

**CONSENT**

- Verification of inclusion / exclusion criteria
- Consent signature
- Collection of urine sample for pregnancy test

**DATA COLLECTION**

Questionnaire : **Case Report Form (CRF)**

- Module 1 : Screening and Enrollment
- Module 2 : Sociodemographic Information
- Module 3 : Behavioral Risk Assessment
- Module 4 : General health and medical history including medication, smoke and alcohol
- Module 5 : Pregnancy and Contraception History
- Module 6 : HIV testing/status and treatment
- Module 7 : Gynaecological Physical Exam
- Module 8 : Sample collection and results

**SAMPLE COLLECTION**

- Vaginal swabs sample collection
- pH and smear slide
- GIFT Test near the patient
- Finger prick blood sample collection for HIV test

**LABORATORY ANALYSIS**

- GIFT test in the laboratory -Test reading using a lateral flow test automated reader
- STI/BV tests : NAAT for CT/NG/TV
- Nugent scoring
- HIV test

**LABORATORY RESULTS**

- Treatment according syndromic approach OR appreciation of clinician
- Treatment of the participant and partners
- If positive HIV test : refer the participant to clinician

Section & Topic	No	Item	Reported on page #
<b>TITLE OR ABSTRACT</b>			
	<b>1</b>	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)	1 Performance includes sensitivity, specificity, PPV, NPV, accuracy
<b>ABSTRACT</b>			
	<b>2</b>	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)	4-5
<b>INTRODUCTION</b>			
	<b>3</b>	Scientific and clinical background, including the intended use and clinical role of the index test	6-8
	<b>4</b>	Study objectives and hypotheses	8-10; Table 1
<b>METHODS</b>			
<i>Study design</i>	<b>5</b>	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)	10-13
<i>Participants</i>	<b>6</b>	Eligibility criteria	13-14; Table 2
	<b>7</b>	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)	12-14
	<b>8</b>	Where and when potentially eligible participants were identified (setting, location and dates)	12-14
	<b>9</b>	Whether participants formed a consecutive, random or convenience series	12-14, fig 1
<i>Test methods</i>	<b>10a</b>	Index test, in sufficient detail to allow replication	Not assigned as it is a study protocol, will be detailed in the paper reporting the results
	<b>10b</b>	Reference standard, in sufficient detail to allow replication	19, more details will be included in the paper reporting the results
	<b>11</b>	Rationale for choosing the reference standard (if alternatives exist)	20 - 21, 22
	<b>12a</b>	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory	21, more details will be included in the paper reporting the results

1		<b>12b</b> Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory	21, more details will be included in the paper reporting the results
2			
3			
4			
5			
6		<b>13a</b> Whether clinical information and reference standard results were available to the performers/readers of the index test	19, reference performed later on and elsewhere than the study site
7			
8			
9			
10			
11		<b>13b</b> Whether clinical information and index test results were available to the assessors of the reference standard	19
12			
13			
14	<i>Analysis</i>	<b>14</b> Methods for estimating or comparing measures of diagnostic accuracy	21-22
15			
16		<b>15</b> How indeterminate index test or reference standard results were handled	Not assigned as it is a study protocol
17			
18			
19		<b>16</b> How missing data on the index test and reference standard were handled	Not assigned as it is a study protocol
20			
21			
22			
23		<b>17</b> Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory	Not assigned as it is a study protocol
24			
25			
26			
27		<b>18</b> Intended sample size and how it was determined	14-15
28			
29	<b>RESULTS</b>		
30	<i>Participants</i>	<b>19</b> Flow of participants, using a diagram	Fig 1
31			
32		<b>20</b> Baseline demographic and clinical characteristics of participants	Not assigned as it is a study protocol
33			
34			
35			
36		<b>21a</b> Distribution of severity of disease in those with the target condition	Not assigned as it is a study protocol
37			
38			
39		<b>21b</b> Distribution of alternative diagnoses in those without the target condition	Not assigned as it is a study protocol
40			
41			
42			
43		<b>22</b> Time interval and any clinical interventions between index test and reference standard	Not assigned as it is a study protocol
44			
45			
46	<i>Test results</i>	<b>23</b> Cross tabulation of the index test results (or their distribution) by the results of the reference standard	Not assigned as it is a study protocol
47			
48			
49			
50		<b>24</b> Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)	Not assigned as it is a study protocol
51			
52			
53		<b>25</b> Any adverse events from performing the index test or the reference standard	Not assigned as it is a study protocol
54			
55			
56	<b>DISCUSSION</b>		
57			
58			
59			
60			

1		<b>26</b> Study limitations, including sources of potential bias, statistical uncertainty, and generalisability	24
2			
3			
4		<b>27</b> Implications for practice, including the intended use and clinical role of the index test	23-24
5			
6	<b>OTHER</b>		
7	<b>INFORMATION</b>		
8		<b>28</b> Registration number and name of registry	5, 23
9			
10		<b>29</b> Where the full study protocol can be accessed	<a href="http://clinicaltrials.gov">clinicaltrials.gov</a>
11			public registry
12			(NCT05723484)
13			
14		<b>30</b> Sources of funding and other support; role of funders	27
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

# STARD 2015

---

## AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

---

## EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having a **target condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

---

## DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.